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General: All reactions were carried out under Ar in flame-dried glassware. The solvents used 
were purified by distillation over the drying agents indicated and were transferred under Ar: 
THF, Et2O (Mg/anthracene), CH2Cl2, Et3N, CH3CN, DMSO, (CaH2), pentane, hexane, 
toluene (Na/K), DMF (Desmodur 15, dibutyl tin dilaurat), MeOH, EtOH (Mg). Flash 
chromatography (FC): Merck silica gel 60 (230–400 mesh). NMR: Spectra were recorded on 
Bruker DPX 300, AMX 300, AV 400, DPX 600 and AVIII 600 spectrometer in the solvents 
indicated; chemical shifts (δ) are given in ppm relative to TMS, coupling constants (J) in Hz. 
The solvent signals were used as references and the chemical shifts converted to the TMS 
scale (CDCl3: δC ≡ 77.0 ppm; residual CHCl3 in CDCl3: δH ≡ 7.26 ppm; CD2Cl2: δC ≡ 53.8 
ppm; residual 1H: δH ≡ 5.32 ppm; CD3OD δC ≡ 49.0 ppm; residual 1H: δH ≡ 3.30 ppm; [D]8-
acetone: δC ≡ 29.8 ppm; residual 1H: δH ≡ 2.05 ppm). Where indicated, the signal assignments 
are unambiguous; the numbering scheme is arbitrary as shown in the inserts. The assignments 
are based upon 1D and 2D spectra recorded using the following pulse sequences from the 
Bruker standard pulse program library: DEPT; COSY (cosygs, cosydqtp, and cosygpqf); 
HSQC (invietgssi, and hsqcedetgpsisp2.2) optimized for 1J(C,H) = 145 Hz; HMBC 
(inv4gslplrnd, and hmbcetgpl3nd); for correlations via nJ(C,H); HSQC-TOCSY (invietgsml) 
using an MLEV17 mixing time of 120 ms; NOESY (noesygpph). IR: Magna IR750 (Nicolet) 
or Spectrum One (Perkin-Elmer) spectrometer, wavenumbers (ν~ ) in cm-1; MS (EI): Finnigan 
MAT 8200 (70 eV), ESI-MS: ESQ3000 (Bruker), accurate mass determinations: Bruker 
APEX III FT-MS (7 T magnet) or Mat 95 (Finnigan). Melting points: Büchi melting point 
apparatus B-540 (corrected). Elemental analyses: H. Kolbe, Mülheim/Ruhr. All commercially 
available compounds (Fluka, Lancaster, Aldrich) were used as received. 
 
Building blocks 
(S)-1-Hepten-4-ol (10a): A solution of EtMgCl (2 M in THF, 16.2 mL, 32.4 mmol) was 
added dropwise to a solution of (S)-epichlorohydrine 7 (2.00 g, 21.6 mmol) and CuCN (193 
mg, 2.16 mmol) in THF (30 mL) at −78 °C. The mixture was warmed to −20 °C over 3 h 
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before it was poured into sat. aq. NH4Cl. The organic layer was separated, the aqueous phase 
was extracted with Et2O, the combined organic layers were dried over MgSO4, filtered and 
evaporated to afford crude (S)-1-chloro-pentan-2-ol (8a), which was used without further 
purification. 
 
Powdered NaOH (4.80 g, 121 mmol) was added to a solution of the crude 8a in Et2O (30 mL) 
and the resulting mixture was stirred at room temperature for 22 h before it was poured into 
water (10 mL). The organic layer was separated, the aqueous layer was repeatedly extracted 
with Et2O (3 x 10 mL), the combined organic phases were dried over MgSO4, filtered and 
evaporated to give (S)-2-propyloxirane (9a), which was used without further purification.  
 
To a stirred solution of crude 9a thus formed and CuCN (193 mg, 2.16 mmol) in THF (15 
mL) was added a solution of vinylmagnesium bromide (1 M in THF, 28.1 mL, 28.1 mmol) at 
−78 °C over a period of 45 min. The resulting mixture was allowed to warm to 0 °C before 
the reaction was quenched with sat. aq. NH4Cl. The aqueous layer was repeatedly extracted 
with Et2O, the combined ethereal extracts were washed with brine, dried over MgSO4, filtered 
and evaporated. The residue was purified by flash chromatography (hexanes/tert-butyl methyl 
ether, 4/1) to give 10a as a pale yellow oil (1.91 g, 77 %). The NMR data are in full 
agreement with those previously reported in the literature.1 [ ]20Dα  = –12.8 (c = 0.52, CHCl3); 
lit.  = +12.7 (c = 0.54, CHCl3) for (R)-enantiomer (99 % ee). [ ]20Dα
 
(S)-Non-1-en-4-ol (10b): Prepared analogously as a colorless oil (1.34 g, 74 % overall). 
 = −7.7 (c = 1.52, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 5.84 (dddd, J = 12.0, 9.4, 
7.9, 6.5 Hz, 1 H), 5.15-5.17 (m, 1 H), 5.11-5.13 (m, 1 H), 3.66 (ddt, J = 9.8, 7.8, 4.9 Hz, 1 H), 
2.28-2.35 (m, 1 H), 2.11-2.18 (m, 1 H), 1.28-1.59 (m, 8 H), 0.90 (t, J = 7.0 Hz, 3 H); 13C 
NMR (100 MHz, CDCl3): δ = 135.2, 118.3, 70.9, 42.2, 37.0, 32.1, 25.6, 22.8, 14.2; IR (film): 
[ ]20Dα
ν~  = 3372, 3077, 2956, 2930, 2857, 1641, 1466, 1378, 1124, 1029, 994, 912, 725; MS (EI): 
                                                 
1 S.-K. Kang, D.-C. Park, H.-S. Rho, C.-M. Yu, J.-H. Hong, Synth. Commun. 1995, 25, 203-214. 
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m/z (%): 124 (1) [M+], 101 (24), 83 (70), 57 (12), 55 (100), 43 (30), 41 (37), 29 (18); HRMS 
(CI): m/z: calcd for C9H19O [M+ + H]: 143.1436, found: 143.1435. 
 
Compound 12a: A solution of HBr in HOAc (30 % w/w, 7.1 mL) was added dropwise to a 
cold (0 °C) solution of 1,2,3,4-tetra-O-acetyl-D-fucopyranose (2.08 g, 6.26 mmol)2 in CH2Cl2 
(10 mL) and Ac2O (0.96 mL) and the resulting mixture was stirred for 0.5 h at room 
temperature once the addition was complete. The mixture was then concentrated in vacuo and 
the resulting oil was azeotroped with toluene (3 x 10 mL) to give crude glycosyl bromide 11 
which was used in the following step without further purification.  
 
A solution of the crude bromide 11 prepared above in CH2Cl2 (120 mL) was added to a 
suspension of activated MS 4 Å in CH2Cl2 (50 mL) and the resulting mixture was stirred at 
room temperature for 10 min before (S)-1-hepten-4-ol (10a) (476 mg, 4.17 mmol), 2,6-di-tert-
butylpyridine (2.40 g, 12.5 mmol) and AgOTf (1.90 g, 7.32 mmol) were successively added. 
Stirring was continued for 14 h before the suspension was filtered through a pad of Celite. 
The filtrate was evaporated and the residue purified by flash chromatography (hexanes/tert-
butyl methyl ether, 6/1) to give compound 12a as a colorless syrup (1.36 g, 84 %).  = 
−20.1 (c = 0.73, CHCl3). 1H NMR (400 MHz, CDCl3): δ = 5.77 (ddt, J = 17.2, 10.2, 7.0 Hz, 1 
H), 5.21 (dd, J = 3.5, 1.1 Hz, 1 H), 5.17-4.99 (m, 4 H), 4.48 (d, J = 7.9 Hz, 1 H), 3.76 (dq, J = 
6.5, 1.0 Hz, 1 H), 3.64 (m, 1 H), 2.25-2.22 (m, 2 H), 2.17 (s, 3 H), 2.04 (s, 3 H), 1.98 (s, 3 H), 
1.63-1.34 (m, 4 H), 1.20 (d, J = 6.7 Hz, 3 H), 0.89 (t, J = 7.3 Hz, 3 H); 13C NMR (100 MHz, 
CDCl3): δ  = 170.8, 170.3, 169.4, 134.4, 117.1, 100.4, 79.7, 71.5, 70.4, 69.3, 68.9, 38.4, 36.6, 
20.9, 20.7, 20.6, 18.3, 16.1, 14.0; IR (film): 
[ ]20Dα
ν~  = 3076, 2961, 2937, 2873, 1752, 1641, 1368, 
1250, 1223, 1074, 915; MS (EI): m/z (%): 273 (27), 157 (17), 153 (25), 115 (13), 111 (24), 83 
(12), 55 (23), 43 (100); HRMS (ESI): m/z: calcd for C19H30O8Na [M+ + Na]: 409.18314, 
found: 409.18329. 
 
                                                 
2 K. C. Nicolaou, C. W. Hummel, M. Nakada, K. Shibayama, E. N. Pitsinos, H. Saimoto, Y. Mizuno, K.-U. 
Baldenius, A. L. Smith, J. Am. Chem. Soc. 1993, 115, 7625-7635. 
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Compound 12b: Prepared analogously as a colorless syrup (602 mg, 67 %). 1H NMR (400 
MHz, CDCl3): δ = 5.77 (ddt, J = 17.2, 10.2, 7.0 Hz, 1 H), 5.22 (dd, J = 3.5, 1.0 Hz, 1 H), 5.16 
(dd, J = 10.5, 7.9 Hz, 1 H), 5.07 (ddt, J = 4.2, 2.2, 1.2 Hz, 1 H), 4.98-5.04 (m, 2 H), 4.48 (d, 
J = 7.9 Hz, 1 H), 4.13 (q, J = 7.1 Hz, 1 H), 3.77 (qd, J = 6.4, 0.9 Hz, 1 H), 3.63 (pent., J = 5.9 
Hz, 1 H), 2.24 (t, J = 6.2 Hz, 2 H), 2.17 (s, 3 H), 2.04 (s, 3 H), 1.98 (s, 3 H), 1.23-1.61 (m, 7 
H), 1.20 (d, J = 6.4 Hz, 3 H), 0.89 (t, J = 6.8 Hz, 3 H); 13C NMR (100 MHz, CDCl3): δ = 
171.0, 170.5, 169.7, 134.7, 117.3, 100.8, 80.4, 71.8, 70.6, 69.5, 69.2, 38.7, 34.6, 32.0, 24.9, 
22.8, 21.1, 21.0, 20.9, 16.3, 14.3; IR (film): ν~  = 3078, 2985, 2955, 2934, 2861, 1749, 1436, 
1367, 1249, 1220, 1173, 1073, 1016, 913, 727; MS (EI): m/z (%): 273 (52), 213 (12), 184 
(17), 171 (15), 157 (34), 153 (48), 142 (16), 115 (23), 111 (40), 83 (17), 69 (14), 55 (12), 43 
(100); HRMS (ESI): m/z: calcd for C21H34O8Na [M+ + Na]: 437.2146, found: 437.2145. 
 
Compound 13a: Compound 12a (1.92 g, 4.97 mmol) was dissolved in MeOH (20 mL) and 
treated with KOMe (18 mg, 0.25 mmol) for 3 h. The mixture was neutralized with HCl (1 M) 
and the solvent was evaporated. The residue was suspended in EtOAc, the mixture passed 
through a short-pad of silica to remove the inorganic salts, and the filtrate was evaporated. A 
solution containing the resulting crude product, 2,2’-dimethoxypropane (4.4 mL) and 
TsOH·H2O (ca. 20 mg) in acetone (15 mL) was stirred at room temperature for 15 h. For 
work-up, the solvent was evaporated and the residue purified by flash chromatography 
(hexanes/EtOAc, 6/1 → 4/1) to give glycoside 13a as a colorless syrup (1.46 g, 98 %). 
 = +3.4 (c = 1.18, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 5.83 (ddt, J = 17.1, 10.1, 
7.2 Hz, 1 H), 5.13-5.08 (m, 2 H), 4.17 (d, J = 8.2 Hz, 1 H), 4.04-3.98 (m, 2 H), 3.83 (dq, J = 
6.6, 2.2 Hz, 1H), 3.72-3.66 (m, 1 H), 3.50 (dd, J = 8.2, 7.3 Hz, 1 H), 2.35-2.23 (m, 3 H), 1.65-
1.33 (m, 13 H), 0.91 (t, J = 7.3 Hz, 3 H); 13C NMR (100 MHz, CDCl3): δ = 134.9, 117.6, 
109.8, 101.6, 78.8, 78.7, 76.3, 73.8, 69.1, 38.7, 37.0, 28.2, 26.3, 18.4, 16.6, 14.0; IR (film): 
[ ]20Dα
ν~  = 3483, 3076, 2983, 2959, 2935, 2872, 1641, 1380, 1073, 1036, 990, 918; MS (EI): m/z 
(%): 187 (84), 129 (16), 113 (12), 101 (43), 100 (37), 97 (19), 85 (20), 83 (26), 73 (22), 71 
(45), 59 (100), 57 (34), 55 (79), 43 (72), 41 (36), 29 (20); HRMS (ESI): m/z: calcd for 
C16H28O5Na [M+ + Na]: 323.18287, found: 323.18290. 
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Compound 13b: Prepared analogously as a colorless syrup (757 mg, 83 %). [ ]  = +8.8 (c = 
0.8, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 5.84 (ddt, J = 17.1, 10.2, 7.1 Hz, 1 H), 5.09-
5.14 (m, 2 H), 4.18 (d, J = 8.3 Hz, 1 H), 4.03 (dd, J = 7.2, 5.5 Hz, 1 H), 3.99 (dd, J = 5.5, 2.2 
Hz, 1 H), 3.84 (qd, J = 6.6, 2.1 Hz, 1 H), 3.65-3.71 (m, 1 H), 3.51 (dd, J = 8.2, 7.3 Hz, 2 H), 
2.24-2.34 (m, 2 H), 1.54 (s, 3 H), 1.50-1.68 (m, 2 H), 1.41 (d, J = 6.6 Hz, 3 H), 1.36 (s, 3 H), 
1.22-1.39 (m, 6 H), 0.89 (t, J = 7.0 Hz, 3 H); 13C NMR (100 MHz, CDCl3): δ = 135.2, 117.8, 




ν~  = 3477, 3074, 2984, 2934, 2862, 1641, 1457, 1380, 1244, 1218, 1181, 1154, 
1129, 1069, 1034, 991, 916, 869, 801, 687; MS (EI): m/z (%): 313 (4), 287 (4), 187 (100), 129 
(19), 113 (13), 101 (36), 100 (35), 99 (57), 85 (17), 83 (20 ), 55 (30), 43 (41), 29 (11); HRMS 
(ESI): m/z: calcd for C18H32O5Na [M+ + Na]: 351.2153, found: 351.2142. 
 
(Z)-(3-Iodo-3-phenylallyloxy)dimethyl(phenyl)silane (23): Alcohol 22 (1.6 mL, 12.83 
mmol) was added dropwise to a solution of sodium bis(2-methoxyethoxy)aluminum hydride 
(RED-Al, 7.75 mL, 25.7 mmol) in Et2O (43 mL) at 0 °C and the resulting dark mixture was 
stirred at ambient temperature for 4 h. For work up, the mixture was cooled to 0 °C and the 
reaction quenched by slow addition of EtOAc (1.25 mL, 12.83 mmol). After additional 15 
min at 0 °C, the mixture was cooled to −78 °C before I2 (4.89 g, 19.25 mmol) was added in 
one portion. The mixture was allowed to reach room temperature over the course of 5 h before 
it was quenched with aq. sat. Na2S2O3 (20 mL). The resulting mixture was diluted with water 
(20 mL), the aqueous layer was extracted with tert-butyl methyl ether (3 x 100 mL), the 
combined organic layers were dried over MgSO4 and evaporated, and the residue was purified 
by flash chromatography (hexanes/Et2O, 20:1) to give (Z)-3-iodo-3-phenylprop-2-en-1-ol 
(2.86 g, 86 %) as a pale yellow oil, which analyzed as follows: 1H NMR (300 MHz, CDCl3): 
δ = 7.47-7.51 (m, 2 H), 7.28-7.36 (m, 3 H), 6.27 (t, J = 5.7 Hz, 1 H), 4.40 (d, J = 5.7 Hz, 2 H), 
1.75 (br. s, 1 H); 13C NMR (75 MHz, CDCl3): δ = 142.4, 137.2, 128.9, 128.6, 128.5, 105.3, 
68.5; IR (film): ν~  = 3325, 3081, 3058, 2912, 2874, 1622, 1591, 1573, 1487, 1442, 1217, 
1033, 853, 751, 692; MS (EI): m/z (%): 261 (1) [M+ + 1], 260 (18) [M+], 133 (100), 115 (16), 
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105 (26), 104 (13), 103 (79), 102 (22), 77 (30), 55 (37), 51 (13); HRMS (EI): m/z: calcd for 
C9H9IO: 259.9698, found: 259.9699.  
 
Et3N (1.531 mL, 10.98 mmol) was added to a solution of this alcohol (2.80 g, 10.77 mmol) in 
CH2Cl2 (54 mL) at 0 °C and the mixture was stirred for 10 min before a solution of 
chlorodimethylphenylsilane (1.84 mL, 10.98 mmol) in CH2Cl2 (10 mL) was added over 15 
min. Stirring was continued at 0 °C for 2 h before the reaction was quenched with aq. sat. 
NH4Cl (25 mL). The aqueous layer was extracted with CH2Cl2 (50 mL), the combined 
organic phases were dried over Na2SO4 and evaporated, and the residue was purified by flash 
chromatography (hexanes/Et2O, 20:1) to give product 23 as a pale yellow oil (4.09 g, 96 %). 
1H NMR (300 MHz, CDCl3): δ = 7.46-7.49 (m, 2 H), 7.24-7.28 (m, 5 H), 7.11-7.15 (m, 3 H), 
6.03 (t, J = 5.2 Hz, 1 H), 4.24 (d, J = 5.2 Hz, 2 H), 0.32 (s, 6 H); 13C NMR (75 MHz, CDCl3): 
δ = 143.4, 139.1, 138.6, 134.7, 131.0, 129.7, 129.6, 129.4, 129.2, 104.1, 70.4, −0.5; IR (film): 
ν~  = 3069, 3022, 2956, 2865, 1623, 1591, 1575, 1488, 1443, 1427, 1252, 1116, 1059, 877, 
826, 787, 741, 694; MS (EI): m/z (%): 394 (1) [M+], 267 (36), 247 (13), 194 (12), 193 (75), 
165 (12), 136 (13), 135 (100), 115 (25), 91 (15), 75 (25); HRMS (ESI): m/z: calcd for 
C17H19OISiNa [M+ +Na]: 417.0148, found: 417.0150. 
 
(Z)-3-(Dimethyl(phenyl)silyl)-3-phenylprop-2-en-1-ol (24): tBuLi (1.5 M in pentane, 3.72 
ml, 5.58 mmol) was added over 10 min to a solution of vinyl iodide 23 (1.00 g, 2.54 mmol) in 
THF (13 mL) at −78 °C. After stirring for 2 h at that temperature, the reaction was quenched 
with aq. sat. NH4Cl (20 mL), the aqueous layer was extracted with tert-butyl methyl ether (3 x 
25 mL), the combined extracts were dried over MgSO4 and evaporated, and the residue was 
purified by flash chromatography (hexanes/Et2O, 5:1) to give vinylsilane 24 (385 mg, 57 %) 
as a colorless syrup. 1H NMR (300 MHz, CDCl3): δ = 7.45-7.48 (m, 2 H), 7.24-7.28 (m, 3 H), 
7.05-7.19 (m, 3 H), 6.99-6.95 (m, 2 H), 6.24 (t, J = 6.9 Hz, 1 H), 3.98 (d, J = 6.8 Hz, 2 H), 
1.27 (br. s, 1 H), 0.22 (s, 6 H); 13C NMR (75 MHz, CDCl3): δ = 146.0, 145.4, 144.9, 139.4, 
133.9, 129.5, 128.4, 128.2, 127.6, 126.2, 62.5, −0.2; IR (film): ν~  = 3337, 3069, 3052, 3019, 
3022, 2956, 2898, 1596, 1489, 1441, 1427, 1251, 1110, 1030, 881, 811, 778, 731, 700; MS 
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(EI): m/z (%): 268 (0.6) [M+], 253 (10), 250 (31), 236 (13), 235 (54), 191 (18), 190 (30), 175 
(48), 173 (23), 137 (59), 135 (100), 116 (45), 115 (70), 107 (14), 105 (15), 91 (14), 75 (72), 
45 (11), 43 (15); HRMS (ESI): m/z: calcd for C17H20OSiNa [M+ + Na]: 291.1176, found: 
291.1174. 
 
(Z)-3-Dimethyl(phenyl)silyl-2-propenoic acid (26): Oxalyl chloride (0.13 mL, 1.49 mmol) 
was added dropwise at −78 °C to a solution of DMSO (0.21 mL, 2.99 mmol) in CH2Cl2 (5 
mL) and the mixture as stirred for 15 min at that temperature. A solution of alcohol 24 (267 
mg, 1.00 mmol) in CH2Cl2 (2.0 mL) was introduced and the resulting suspension was stirred 
for 45 min, at which point Et3N (0.56 mL, 3.98 mmol) was added. The mixture was allowed 
to warm to 0 °C over 1.5 h before the reaction was quenched with sat. aq. NH4Cl. The 
aqueous layer was repeatedly extracted with ether, the combined organic phases were washed 
with brine, dried over Na2SO4, and the solvent was evaporated to afford the corresponding 
aldehyde 25 as a pale yellow oil which was used without further purification (239 mg, 90 %). 
Characteristic data: 1H NMR (400 MHz, CD2Cl2): δ = 9.83 (d, J = 8.4 Hz, 1 H), 7.61-7.58 (m, 
2 H), 7.42-7.30 (m, 6 H), 7.16-7.13 (m, 2 H), 6.51 (d, J = 8.4 Hz, 1 H), 0.34 (s, 6 H); 13C 
NMR (100 MHz, CD2Cl2): δ = 192.9, 168.4, 144.6, 143.7, 138.2, 134.1, 130.0, 128.6, 127.8, 
126.7, 0.3; IR (film): ν~  = 2839, 2739, 1677, 1489, 1428, 1254, 1111, 814, 783, 733, 701, 
641, 472; MS (EI): m/z (%): 135 (51), 189 (78), 251 (100), 266 (9); HRMS (ESI): m/z: calcd 
for C17H18OSiNa [M+ + Na]: 289.10192, found: 289.10184.  
 
A solution of NaH2PO4 (73 mg, 0.61 mmol) in water (0.48 mL), 2-methyl-2-butene (0.21 
mL), and NaClO2 (109 mg, 1.2 mmol) were successively added to a solution of the crude 
aldehyde 25 (100 mg, 0.38 mmol) in tBuOH (3.0 mL). The mixture was stirred for 2.5 h, all 
volatiles were evaporated, and the residue was purified by flash chromatography 
(hexanes/EtOAc/AcOH, 100:10:0.1) to give acid 26 (99.8 mg, 93 %) as a white solid. M.p. = 
77-78 °C. 1H NMR (400 MHz, CDCl3): δ =7.51-7.49 (m, 2 H), 7.30-7.24 (m, 6 H), 7.08-7.05 
(m, 2 H), 6.44 (s, 1 H), 0.37 (s, 6 H); 13C NMR (100 MHz, CDCl3): δ = 166.9, 144.8, 138.2, 
133.7, 132.9, 128.7, 128.0, 127.5, 126.9, 126.4, 95.7, –0.9; IR (film): ν~  = 3022, 2954, 1694, 
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1589, 1489, 1410, 1313, 1251, 815, 701; MS (EI): m/z (%): 75 (20), 205 (60), 267 (100), 282 
(1); HRMS (EI): m/z: calcd for C17H17O2Si: 281.10033, found: 281.10064. 
 
dl-5-Hydroxy-5-(2-furyl)-1-pentene (rac-40): Magnesium turnings (335 mg, 13.8 mmol) in 
THF (1 mL) were activated with 1,2-dibromoethane (25 μL) before additional THF (7.0 mL) 
was added. A solution of 1-bromo-3-pentene (1.70 g, 12.5 mmol) in THF (2.0 mL) was 
introduced over 30 min and the mixture was stirred at ambient temperature for 1 h. The 
solution of the resulting Grignard reagent was cooled to 0 °C before aldehyde 39 (1.0 g, 10.4 
mmol) was added at that temperature. After 2 h, the mixture was quenched with aq. HCl (5 
mL, 1 M), the aqueous layer was repeatedly extracted with Et2O, and the combined ethereal 
phases were washed with brine, dried over MgSO4, filtered and evaporated. The residue was 
purified by flash chromatography (hexanes/EtOAc, 9/1) to give product rac-40 as a pale 
yellow oil (1.30 g, 82%), which should be quickly used in the next step or stored at −78 °C. 
1H NMR (400 MHz, CDCl3): δ =7.37 (dd, J = 1.8, 0.8 Hz, 1 H), 6.33 (dd, J = 3.2, 1.8 Hz, 1 
H), 6.24 (d, J = 3.2 Hz, 1 H), 5.84 (ddt, J = 17.0, 10.3, 6.6 Hz, 1H), 5.08-4.97 (m, 2 H), 4.70 
(t, J = 6.7 Hz, 1 H), 2.20-2.12 (m, 2 H), 1.98-1.92 (m, 3 H); 13C NMR (100 MHz, CDCl3): δ = 
156.6, 142.0, 137.8, 115.2, 110.1, 105.9, 67.2, 34.6, 29.7; IR (film): ν~  = 3366, 2943, 2863, 
1641, 1505, 1149, 1066, 1009, 913, 738, 599; MS (EI): m/z (%): 152 (3), 134 (5), 123 (3), 110 
(23), 97 (100), 69 (12), 41 (35), 39 (28), 29 (12), 27 (13); HRMS (EI): m/z: calcd for 
C9H12O2: 152.08358, found: 152.08373. 
 
Kinetic resolution: preparation of (−)-40. D-(–)-DIPT (2.50 g, 11.8 mmol) was added to a 
solution of Ti(OiPr)4 (2.90 mL, 9.86 mmol) in CH2Cl2 (45 mL) at −20 °C. After stirring for 
10 min, the mixture was cooled to −30 °C and a solution of rac-40 (1.50 g, 9.86 mmol) in 
CH2Cl2 (2 mL) was slowly introduced. After stirring for 30 min, a solution of tert-
butylhydroperoxide (5 M in decane, 1.18 mL, 5.92 mmol) was added, and the mixture was 
stirred for 24 h at −20 °C. For work-up, the mixture was filtered through a pad of silica and 
the filtrate was evaporated. The residue was purified by flash chromatography 
(hexanes/EtOAc, 9/1) to give (−)-40 as a pale yellow oil (701 mg, 47 %, > 99 % ee), which 
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should be quickly used in the next step or stored at −78 °C. The ee was determined by HPLC 
(Chiralcel OB-H, hexane/iPrOH = 95/5). The NMR data are identical with those of the 
racemic sample described above. [ ]  = –6.6 (c = 1.12, CHCl3). 20Dα
 
Compound 41: To a solution of alcohol (−)-40 (333 mg, 2.19 mmol) and VO(acac)2 (6.00 
mg, 0.023 mmol) in CH2Cl2 (2.0 mL) was added tert-butylhydroperoxide (TBHP, 5 M in 
decane, 0.44 mL, 2.19 mmol). After stirring for 1 h at room temperature, additional 
VO(acac)2 (6.00 mg, 0.023 mmol) and TBHP (0.44 mL, 2.19 mmol) were added and stirring 
was continued for 2 h. The mixture was then passed through a short pad of silica, the filtrate 
was evaporated, and the residue purified by flash chromatography (hexanes/EtOAc, 4/1) to 
give compound 41 as a mixture of diastereomers (262 mg, 71 %, major/minor = 69/31). 1H 
NMR (400 MHz, CDCl3): δ =6.94 (dd, J = 10.3, 1.5 Hz, 1 H of minor isomer), 6.90 (dd, J = 
10.3, 3.5 Hz, 1 H of major isomer), 6.16 (dd, J = 10.3, 1.6 Hz, 1 H of minor isomer), 6.11 (d, 
J = 10.3 Hz, 1 H of major isomer), 5.87-5.76 (m, 1 H), 5.66-5.65 (m, 1 H), 5.18-4.98 (m, 2 
H), 4.59 (dd, J = 8.3, 3.8 Hz, 1 H of major isomer), 4.11 (ddd, J = 8.6, 3.8, 1.2 Hz, 1 H of 
minor isomer), 3.34 (br, 1 H of minor isomer), 3.06 (br, 1 H of major isomer), 2.24-2.18 (m, 2 
H), 2.07-2.03 (m, 1 H), 1.18-1.74 (m, 1 H); 13C NMR (100 MHz, CDCl3): δ = 196.5 (major), 
196.1 (minor), 147.6 (minor), 144.2 (major), 137.7 (major), 137.5 (minor), 128.8 (minor), 
127.7 (major), 115.5 (minor), 115.4 (major), 90.9 (minor), 87.7 (major), 78.0 (minor), 73.3 
(major), 29.7 (minor), 29.1 (minor), 29.0 (major), 28.8 (major); IR (film): ν~  = 3411, 3077, 
2926, 1690, 1641, 1089, 1033, 916; MS (EI): m/z (%): 168 (4), 114 (20), 84 (100), 56 (28), 55 
(39), 39 (10), 29 (12), 28 (12), 27 (14); HRMS (EI): m/z: calcd for C9H12O3: 168.07864, 
found: 168.07852. 
 
Compound 42: Jones’ reagent (1.7 mL)3 was added dropwise to an ice-cold solution of 
hemiacetal 41 (413 mg, 2.46 mmol) in acetone (13 mL). The resulting mixture was stirred for 
3 h at room temperature before the mixture was diluted with tert-butyl methyl ether (50 mL) 
                                                 
3 M. P. Georgiadis, A. Tsekouras, S. I. Kotretsou, S. A. Haroutounian, M. G. Polissiou, Synthesis 1991, 929-
932. 
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and washed with water. The organic phase was dried over Na2SO4, filtered, and evaporated to 
give the crude oxidation product.  
 
To a solution of this material in CHCl3 (26 mL) and AcOH (17 mL) was added zinc powder 
(1.2 g), the suspension was stirred for 3 h, excess zinc was filtered off through Celite, the 
filtrate was evaporated azeotropically with benzene to remove residual HOAc, and the crude 
product was purified by flash chromatography (hexanes/tert-butyl methyl ether, 2/1 → 1/1) to 
give compound 42 as a colorless oil (324 mg, 78 %). [ ]20Dα  = –246.3 (c = 1.08, CHCl3); 1H 
NMR (400 MHz, CDCl3): δ = 5.77 (ddt, J = 16.9, 10.3, 6.7 Hz, 1 H), 5.11-5.02 (m, 2 H), 4.68 
(dd, J = 8.2, 4.0 Hz, 1 H), 2.93-2.89 (m, 2 H), 2.79-2.64 (m, 2 H), 2.34-2.19 (m, 2 H), 2.13-
2.04 (m, 1 H), 1.96-1.86 (m, 1 H); 13C NMR (100 MHz, CDCl3): δ =205.4, 170.0, 136.5, 
116.4, 82.2, 33.8, 29.6, 28.6, 28.2; IR (film): ν~  = 3079, 2929, 1759, 1735, 1641, 1267, 1171, 
999, 919; MS (EI): m/z (%): 168 (5), 114 (72), 98 (3), 86 (5), 56 (100), 55 (27), 42 (10), 41 
(12), 39 (13), 29 (18), 28 (53), 27 (22); HRMS (EI): m/z: calcd for C9H12O3: 168.07865, 
found: 168.07886. 
 
Compound 43: To a solution of ketolactone 42 (100 mg, 0.59 mmol) and 2-
trimethylsilylethanol (0.17 mL, 1.18 mmol) in CH2Cl2 (1.0 mL) was added p-TsOH·H2O (2 
mg). After stirring for 15 h, the mixture was neutralized with triethylamine and passed 
through a pad of silica which was carefully rinsed with EtOAc. The filtrate was evaporated, 
the residue dissolved in CH2Cl2 (10 mL) and treated with triethylamine (0.50 mL, 3.54 
mmol), Ac2O (0.22 mL, 2.36 mmol) and DMAP (10 mg, 0.08 mmol). After 3 h, the 
suspension was filtered through a pad of silica which was carefully rinsed with EtOAc. 
Evaporation of the solvent followed by flash chromatography of the residue (hexanes/EtOAc, 
10/1) gave compound 43 as a colorless oil (156 mg, 93 %, 97 % ee). The ee was determined 
by HPLC (Chiralcel AD, heptane/iPrOH = 98/2). [ ]20Dα  = –4.3 (c = 0.62, CH2Cl2); 1H NMR 
(400 MHz, CD2Cl2): δ = 5.81 (ddt, J = 17.0, 10.3, 6.6 Hz, 1 H), 5.09-4.98 (m, 3 H), 4.14 (m, 2 
H), 2.78-2.72 (m, 2 H), 2.56-2.51 (m, 2 H), 2.21-2.11 (m, 5 H), 1.92-1.80 (m, 2 H), 0.97 (m, 2 
H), 0.04 (s, 9 H); 13C NMR (100 MHz, CD2Cl2): δ = 206.2, 172.7, 170.8, 137.4, 115.9, 78.0, 
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63.2, 33.7, 30.1, 29.6, 27.9, 20.8, 17.6, –1.5; IR (film): ν~  = 3079, 2954, 1732, 1642, 1249, 
1235, 1063, 996, 919, 860, 839, 695; MS (EI): m/z (%): 43 (47), 73 (100), 117 (33), 133 (10), 
173 (82); HRMS (ESI): m/z: calcd for C16H28O5SiNa [M+ + Na]: 351.15983, found: 
351.15998. 
 
Acid 44: A solution of compound 43 (50 mg, 0.176 mmol) in DMF (1.0 mL) was added to a 
solution of TASF (73 mg, 0.264 mmol) in DMF (1.0 mL). After stirring for 3 h, the mixture 
was filtered through a pad of silica which was rinsed with EtOAc several times, and the 
combined filtrates were evaporated. Flash chromatography (hexanes/EtOAc/HOAc, 2/1/0.01) 
of the residue gave carboxylic acid 44 as a colorless oil (28 mg, 68 %). [ ]20Dα  = –2.1 (c = 0.60, 
CH2Cl2); 1H NMR (400 MHz, CD2Cl2): δ = 5.81 (ddt, J = 17.0, 10.3, 6.7 Hz, 1H), 5.09-4.99 
(m, 3 H), 2.80-2.60 (m, 4 H), 2.20-2.12 (m, 5 H), 1.92-1.80 (m, 2 H); 13C NMR (100 MHz, 
CD2Cl2): δ = 206.1, 177.9, 170.9, 137.4, 115.9, 78.0, 33.5, 30.0, 29.6, 27.5, 20.8; IR (film): 
ν~  = 3079, 2928, 1741, 1731, 1713, 1642, 1237, 999, 918; MS (EI): m/z (%): 43 (100), 85 
(12), 101 (40), 114 (7), 132 (5), 174 (6); HRMS (ESI): m/z: calcd for C11H16O5Na [M+ + Na]: 
251.08899, found: 251.08903. 
 
Compound 48: pTsOH·H2O (4 mg) was added to a solution of compound 42 (200 mg, 1.19 
mmol) and 2-trimethylsilyl ethanol (0.34 mL, 2.38 mmol) in CH2Cl2 (2.0 mL). After stirring 
at room temperature for 2 h, the reaction was quenched with triethylamine and the mixture 
passed through a short pad of silica which was carefully rinsed with EtOAc. The combined 
filtrates were evaporated and the residue purified by flash column chromatography 
(hexanes/EtOAc, 6/1) to give a mixture of the corresponding ester and residual 2-
trimethylsilyl ethanol. PMB trichloroacetimidate (701 mg, 2.48 mmol)4 and TfOH (5 μL, 
0.0573 mmol) were added to a solution of this material in Et2O (12 mL) at 0 °C. After stirring 
for 20 min, triethylamine was introduced and the mixture was filtered through a short pad of 
silica which was carefully rinsed with EtOAc. Evaporation of the combined filtrates and 
purification of the residue by flash chromatography (hexanes/EtOAc, 20/1) gave compound 
                                                 
4 R. Hong, Y. Chen, L. Deng, Angew. Chem. 2005, 117, 3544-3547; Angew. Chem. Int. Ed. 2005, 44, 3478-
3481. 
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48 (307 mg, 63 % over both steps, 97 % ee). The ee was determined by HPLC (Chiralpack 
AD, heptane/iPrOH = 98/2). [ ]  = –26.6 (c = 0.68, CH2Cl2); 1H NMR (400 MHz, CD2Cl2): 
δ = 7.28 (d, J = 8.8 Hz, 2 H), 6.89 (d, J = 8.8 Hz, 2 H), 5.79 (ddt, J = 17.1, 10.5, 6.5 Hz, 1 H), 
5.04-4.96 (m, 3 H), 4.52 (d, J = 11.1 Hz, 1 H), 4.36 (d, J = 11.1 Hz, 1 H), 4.15 (m, 2 H), 3.84 
(dd, J = 7.8, 5.0 Hz, 1 H), 3.80 (s, 3 H), 2.82 (dt, J = 6.6, 2.6 Hz, 2 H), 2.55-2.52 (m, 2 H), 
2.15-2.10 (m, 1 H), 1.78-1.71 (m, 2 H), 0.99 (m, 2 H), 0.05 (s, 9 H); 13C NMR (100 MHz, 
CD2Cl2): δ = 211.5, 173.0, 159.9, 138.2, 130.4, 130.0, 115.4, 114.2, 84.2, 72.5, 63.1, 55.6, 
33.2, 31.9, 29.7, 28.1, 27.1, 17.6, –1.5; IR (film): 
20
Dα
ν~  = 3076, 2953, 2837, 1730, 1641, 1613, 
1586, 1514, 1303, 1250, 1092, 996, 917, 838, 762; MS (EI): m/z (%): 73 (13), 111 (7), 121 
(100), 173 (11), 201 (7), 204 (7); HRMS (ESI): m/z: calcd for C22H34O5SiNa [M+ + Na]: 
429.20677, found: 429.20718. 
 
Acid 49: A solution of 48 (212 mg, 0.52 mmol) in DMF (2.0 mL) was added to a solution of 
TASF (215 mg, 0.78 mmol) in DMF (1.0 mL) and the resulting mixture stirred for 3 h. For 
work up, aq. sat. NH4Cl (100 μL) was added, the mixture filtered through a pad of silica, 
which was rinsed with EtOAc. The combined filtrates were evaporated and the residue was 
purified by flash chromatography (hexanes/EtOAc, 1/1) to give acid 49 as a colorless syrup 
(120 mg, 76 %, 97 % ee). The ee was determined by HPLC (Chiralcel OD-H, 
heptane/iPrOH = 1/1).  = –15.2 (c = 0.46, CH2Cl2); 1H NMR (300 MHz, CD2Cl2): δ = 
7.27 (d, J = 8.7 Hz, 2 H), 6.88 (d, J = 8.7 Hz, 2 H), 5.78 (ddt, J = 17.0, 10.3, 6.6 Hz, 1 H), 
5.04-4.95 (m, 2 H), 4.50 (d, J = 11.1 Hz, 1 H), 4.36 (d, J = 11.1 Hz, 1 H), 3.84 (dd, J = 7.5, 
5.3 Hz, 1 H), 3.79 (s, 3 H), 2.84 (m, 2 H), 2.61 (t, J = 6.2 Hz, 2 H), 2.18-2.09 (m, 2 H), 1.78-
1.69 (m, 2 H); 13C NMR (75 MHz, CD2Cl2): δ = 211.4, 117.8, 159.9, 138.1, 130.2, 130.0, 
115.5, 114.1, 84.1, 72.5, 55.6, 32.9, 31.8, 29.6, 27.5; IR (film): 
[ ]20Dα
ν~  = 3076, 3001, 2936, 1712, 
1641, 1612, 1586, 1514, 1250, 1091, 1034, 917, 822. MS (EI): m/z (%): 77 (3), 78 (3), 91 (2), 
121 (100), 137 (4), 170 (4), 222 (4); HRMS (ESI): m/z: calcd for C17H22O5Na [M+ + Na]: 




Sugar building blocks 
Trichloroacetimidate 15: Trichloroacetonitrile (0.48 mL, 4.79 mmol) and Cs2CO3 (85 mg, 
0.26 mmol) were added to a solution of compound 14 (1.00 g, 2.62 mmol)5 in CH2Cl2 (4 mL) 
and the resulting mixture was stirred for 15 h at ambient temperature before it was filtered 
through a pad of silica. The filtrate was evaporated and the residue purified by flash 
chromatography (hexanes/EtOAc, 2/1) to give trichloroacetimidate 15 as a mixture of 
anomers (1.19 g, 86 %, α:β = 2:1). [ ]20Dα  = +25.9 (c = 0.83, CH2Cl2); 1H NMR (400 MHz, 
CD2Cl2): δ = 8.81 (s, 1 H of β-anomer), 8.71 (s, 1 H of α-anomer), 7.37-7.35 (m, 2 H), 6.89-
6.86 (m, 2 H), 6.53 (d, J = 3.9 Hz, 1 H of α-anomer), 6.00 (d, J = 7.7 Hz, 1 H of β-anomer), 
5.61 (t, J = 9.9 Hz, 1 H of α-anomer), 5.49 (s, 1 H of α-anomer), 5.48 (s, 1 H of β-anomer), 
5.35 (t, J = 8.8 Hz, 1 H of β-anomer), 5.26 (dd, J = 8.6, 7.8 Hz, 1 H of β-anomer), 5.12 (dd, 
J = 9.9, 3.9 Hz, 1H of α-anomer), 4.37 (dd, J = 9.8, 4.3 Hz, 1 H of β-anomer), 4.31 (dd, J = 
10.4, 5.0 Hz, 1 H of α-anomer), 4.13-4.05 (m, 1 H), 4.88-3.72 (m, 5 H), 2.06 (s, 3 H of α-
anomer), 2.04 (s, 3 H of β-anomer), 2.02 (s, 3 H of β-anomer), 2.01 (s, 3 H of α-anomer); 13C 
NMR (100 MHz, CD2Cl2): α-anomer: δ = 170.4, 170.0, 161.3, 160.6, 129.7, 127.8, 113.9, 
102.0, 93.9, 78.9, 70.7, 69.0, 68.7, 67.4, 65.5, 55.6, 21.0, 20.6; β-anomer: δ = 170.4, 169.4, 
161.0, 160.6, 129.7, 127.9, 113.9, 102.0, 96.2, 78.3, 71.8, 71.4, 68.7, 67.4, 65.5, 55.6, 20.9, 
20.7; IR (KBr): ν~  = 3348, 2940, 1754, 1676, 1616, 1589, 1519, 1236, 1071, 1033, 834; MS 
(EI): m/z (%): 527 (22), 365 (9), 179 (16), 137 (51), 136 (100), 135 (71), 43 (85); HRMS (EI): 
m/z: calcd for C20H22Cl3NO9 [M+ + H]: 526.04329, found: 526.04327. 
 
Disaccharide 16a (n = 1): BF3·Et2O (0.25 M in Et2O, 1.90 mL) was added to a solution of 
trichloroacetimidate 15 (746 mg, 1.41 mmol) and alcohol 13a (500 mg, 1.66 mmol) in 
CH2Cl2/pentane (2.0 mL each) at −20 °C. After stirring at that temperature for 30 min, the 
reaction was quenched with sat. aq. NaHCO3 and the mixture diluted with CH2Cl2. The 
organic layer was separated, dried over Na2SO4, and evaporated, and the residue purified by 
flash chromatography (hexanes/EtOAc, 4/1) to give disaccharide 16a as a white solid (696 
mg, 77 %). M.p. = 129-130 °C.  = –35.1 (c = 0.70, CH2Cl2); 1H NMR (400 MHz, [ ]20Dα
                                                 
5 A. Fürstner, K. Radkowski, J. Grabowski, C. Wirtz, R. Mynott, J. Org. Chem. 2000, 65, 8758-8762. 
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CD2Cl2): δ = 7.35 (d, J = 8.8 Hz, 2 H), 6.87 (d, J = 8.8 Hz, 2 H), 5.90 (ddt, J = 17.2, 10.1, 7.2 
Hz, 1 H), 5.46 (s, 1 H), 5.28-5.23 (m, 1 H), 5.10-5.03 (m, 2 H), 5.01 (d, J = 7.6 Hz, 1 H), 
4.95-4.91 (m, 1 H), 4.33 (dd, J = 10.4, 5.0 Hz, 1 H), 4.27 (d, J = 8.0 Hz, 1 H), 4.03-4.00 (m, 1 
H), 3.96 (dd, J = 5.6, 2.1 Hz, 1 H), 3.82-3.49 (m, 9 H), 2.28-2.24 (m, 2 H), 2.05 (s, 3 H), 2.02 
(s, 3 H), 1.52-1.31 (13 H), 0.92 (t, J = 7.2 Hz, 3 H); 13C NMR (100 MHz, CD2Cl2): δ = 170.3, 
169.8, 160.6, 135.7, 130.0, 127.8, 116.8, 113.8, 110.0, 101.8, 100.6, 100.1, 80.2, 79.7, 78.7, 
78.5, 76.9, 73.0, 72.3, 69.0, 68.8, 66.7, 55.6, 38.9, 37.1, 28.1, 26.4, 21.0, 20.9, 18.7, 16.7, 
14.2; IR (film): ν~  = 3073, 2936, 2873, 1755, 1640, 1616, 1518, 1371, 1244, 1219, 1175, 
1099, 1073, 1037, 920, 831; MS (EI): m/z (%): 43 (100), 55 (54), 57 (13), 59 (16), 97 (16), 99 
(78), 100 (45), 109 (14), 121 (14), 127 (14), 135 (28), 136 (26), 137 (38), 169 (26), 179 (53), 
305 (30), 365 (63), 366 (13), 551 (13); HRMS (ESI): m/z: calcd for C34H48O13 [M+ + H]: 
665.31732, found: 665.31667. 
 
Compound 16b (n = 3): Freshly activated MS 4 Å (174 mg) were added to a solution of 
fucoside 13b (600 mg, 1.827 mmol) and trichloroacetimidate 15 (916 mg, 1.740 mmol) in 
CH2Cl2 (17.4 mL) and the resulting solution was stirred for 10 min before it was cooled to 
−30 °C. TMSOTf (31 µL, 0.174 mmol) was then added dropwise and stirring continued for 
45 min at −30 °C before the reaction was quenched with Et3N (0.5 mL). The resulting mixture 
was allowed to reach ambient temperature, the solvents were evaporated, and the residue was 
purified by flash chromatography (hexanes/EtOAc, 10:1→4:1) to give disaccharide 16b as a 
colorless solid (1.15 g, 95 %). M.p. = 134-135 °C;  [ ]20Dα  = −27.8 (c = 0.77, CHCl3); 1H NMR 
(400 MHz, CDCl3): δ = 7.48 (d, J = 8.7 Hz, 2 H), 6.74 (d, J = 8.8 Hz, 2 H), 6.16 (ddt, J = 
17.3, 10.4, 7.1 Hz, 1 H), 5.61 (dd, J = 9.5, 8.8 Hz, 1 H), 5.44 (dd, J = 8.6, 7.5 Hz, 1 H), 5.28 
(s, 1 H), 5.17-5.23 (m, 2 H), 5.08 (d, J = 7.4 Hz, 1 H), 4.27 (d, J = 7.7 Hz, 1 H), 4.25 (dd, J = 
10.6, 4.7 Hz, 1 H), 3.98 (dd, J = 13.3, 7.6 Hz, 1 H), 3.91 (dd, J = 10.4, 7.0 Hz, 1 H), 3.75 (td, 
J = 10.5, 5.9 Hz, 1 H), 3.67 (t, J = 9.5 Hz, 1 H), 3.59 (t, J = 10.2 Hz, 1 H), 3.54 (dd, J = 5.5, 
2.1 Hz, 1 H), 3.39 (td, J = 9.9, 5.0 Hz, 1 H), 3.24 (s, 3 H), 3.19-3.26 (m, 1 H), 2.34-2.46 (m, 2 
H), 1.90 (s, 3 H), 1.74 (s, 3 H), 1.44-1.59 (m, 3 H), 1.31 (d, J = 6.5 Hz, 3 H), 1.24-1.29 (m, 8 
H), 1.25 (s, 3 H), 0.87 (t, J = 7.0 Hz, 3 H); 13C NMR (100 MHz, CDCl3): δ = 170.2, 169.8, 
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161.0, 136.2, 130.7, 128.6, 128.3, 117.3, 114.2, 110.1, 102.3, 101.2, 100.9, 80.4, 80.2, 79.1, 
79.0, 77.1, 74.0, 73.1, 69.2, 68.9, 66.9, 55.1, 39.7, 35.6, 32.6, 28.4, 26.8, 25.6, 23.4, 21.0, 
20.8, 17.1, 14.7; IR (film): ν~  = 2984, 2954, 2035, 2873, 1743, 1695, 1614, 1519, 1377, 1303, 
1245, 1219, 1179, 1073, 1033, 996, 834, 815, 787, 681; MS (EI): m/z (%): 551 (19), 366 (20), 
365 (100), 306 (12), 105 (60), 245 (11), 229 (11), 179 (78), 169 (34), 157 (10), 152 (20), 137 
(45), 136 (27), 135 (32), 132 (11), 127 (18), 121 (17), 109 (18), 100 (50), 99 (81), 83 (12), 69 
(22), 59 (12), 55 (17), 43 (83); HRMS (ESI): m/z: calcd for C36H52O13Na: [M+ + Na]: 
715.3300, found: 715.3298. 
 
Disaccharide 17a (n = 1): A solution of disaccaride 16a (686 mg, 1.06 mmol) and KOMe (10 
mg) in MeOH (10 mL) was stirred for 4 h before it was filtered through a pad of silica and 
evaporated. The residue was purified by flash chromatography (hexanes/EtOAc, 2/1 → 0/1) 
to give disaccharide 17a as a white solid (518 mg, 84 %). M.p. = 68-69 °C. [ ]  = –9.9 (c = 
1.21, CH2Cl2); 1H NMR (400 MHz, CD2Cl2): δ = 7.43 (d, J = 8.8 Hz, 2 H), 6.92 (d, J = 8.8 
Hz, 2 H), 5.95 (ddt, J = 17.2, 10.2, 7.1 Hz, 1 H), 5.52 (s, 1 H), 5.14-5.07 (m, 2 H), 4.69 (d, J = 
7.7 Hz, 1 H), 4.35 (d, J = 8.2 Hz, 1 H), 4.31 (dd, J = 10.5, 4.9 Hz, 1 H), 4.17 (dd, J = 7.4, 5.5 
Hz, 1 H), 4.04 (dd, J = 5.4, 2.1 Hz, 1 H), 3.86-3.44 (m, 12 H), 2.80 (br, 1 H), 2.32 (m, 1 H), 
1.66 (br, 1 H), 1.56-1.30 (m, 13 H), 0.94 (t, J = 7.3 Hz, 3 H); 13C NMR (100 MHz, CD2Cl2): 
δ = 160.6, 135.4, 130.2, 127.9, 116.9, 113.8, 110.4, 104.3, 102.1, 100.2, 96.0, 81.0, 79.2, 
78.6, 77.0, 76.3, 73.2, 69.0, 68.8, 67.3, 55.6, 38.6, 36.9, 28.0, 26.3, 18.5, 16.6, 14.2; IR (film): 
20
Dα
ν~  = 3459, 3072, 2935, 2872, 1640, 1615, 1589, 1518, 1382, 1250, 1075, 1034, 923, 831; MS 
(EI): m/z (%): 41 (18), 43 (20), 55 (63), 57 (25), 59 (25), 69 (14), 73 (14), 85 (14), 97 (14), 99 
(100), 100 (58), 101 (11), 135 (29), 136 (37), 137 (70), 281 (78), 282 (13), 467 (35); HRMS 
(EI): m/z: calcd for C30H45O11 [M+ + H]: 581.29684, found: 581.29659. 
 
Compound 17b (n = 3): Prepared analogously from diacetate 16b (481 mg, 0.695 mmol) as a 
colorless solid (316.2 mg, 76 %). [ ]  = +3.7 (c = 0.88, CHCl3); 1H NMR (300 MHz, C6D6): 
δ = 7.53 (m, 2 H), 6.81 (m, 2 H), 6.15 (m, 1 H), 5.28 (s, 1 H), 5.16 (d, J = 4.7 Hz, 1 H), 5.12 




3.88-4.03 (m, 1 H), 3.90 (dd, J = 15.9, 7.5 Hz, 1 H), 3.70-3.85 (m, 2 H), 3.59 (t, J = 9.9 Hz, 1 
H), 3.35-3.50 (m, 3 H), 3.26 (s, 3 H), 3.21 (dd, J = 6.5, 2.1 Hz, 1 H), 2.75 (br s, 1 H), 2.39 
(dd, J = 6.8, 5.8 Hz, 2 H), 1.48-1.75 (m, 4 H), 1.43 (s, 3 H), 1.22-1.41 (m, 9 H), 1.19 (s, 3 H), 
0.88 (t, J = 6.8 Hz, 3 H); 13C NMR (75 MHz, C6D6): δ = 161.2, 136.3, 131.4, 128.8, 117.5, 
114.3, 110.8, 105.1, 102.6 101.4, 81.8, 81.5, 79.9, 77.4, 77.3, 74.3, 69.5, 69.1, 68.0, 55.4, 
39.8, 35.6, 32.8, 28.5, 26.9, 25.8, 23.6, 17.4, 14.9; IR (film): ν~  = 3468, 3076, 2978, 2934, 
2871, 1615, 1519, 1457, 1379, 1303, 1248, 1173, 1070, 1030, 921, 868, 828, 787, 725, 688; 
HRMS (ESI): m/z: calcd for C32H48O16Na [M+ + Na]: 631.3089, found: 631.3092. 
 
Regioselective acylation: preparation of compound 18a (n = 1): A solution of diol 17a 
(690 mg, 1.19 mmol), DMAP (73.0 mg, 0.60 mmol) and DCC (293 mg, 1.42 mmol) in 
CH2Cl2 (30 mL) was stirred for 5 min prior to the addition of (E)-2-methylbutenoic acid (119 
mg, 1.19 mmol). Stirring was continued overnight and the resulting precipitate was filtered 
off through a pad of silica. The insoluble residues were thoroughly washed with EtOAc and 
the combined filtrates were evaporated. The residue was purified by flash chromatography 
(hexanes/EtOAc, 4/1 → 0/1) to give disaccharide 18a and its regioisomer (ratio ca. 9/1). 
Further purification was performed by preparative HPLC (Nucleodur 100-16-C18/A; 
MeOH/H2O = 4/1; flow rate: 35.0 mL/min; pressure: 4.1 MPa) to give pure 18a (432 mg, 
55 %) and pure regioisomer (45 mg, 6 %), respectively. Analytical and spectroscopic data of 
compound 18a: colorless solid, m.p. = 72-73 °C. [ ]20Dα  = –24.7 (c = 0.42, CH2Cl2); 1H NMR 
(400 MHz, CD2Cl2): δ = 7.33 (d, J = 8.8 Hz, 2 H), 6.91 (m, 1 H), 6.86 (d, J = 8.8 Hz, 2 H), 
5.91 (ddt, J = 17.2, 10.2, 7.1 Hz, 1 H), 5.62 (s, 1 H), 5.24 (d, J = 9.4 Hz, 1 H), 5.11-5.03 (m, 2 
H), 4.77 (d, J = 7.7 Hz, 1 H), 4.34-4.29 (m, 2 H), 4.15-4.12 (m, 1 H), 4.01 (dd, J = 5.4, 2.1 
Hz, 1 H), 3.83-3.50 (m, 9 H), 3.36 (d, J = 2.7 Hz, 1 H), 2.28 (m, 2 H), 1.84-1.78 (m, 6 H), 
1.53-1.33 (m, 14 H), 0.91 (t, J = 7.2 Hz, 3 H); 13C NMR (100 MHz, CD2Cl2): δ = 167.7, 
160.5, 138.3, 135.4, 130.1, 128.6, 127.8, 117.0, 113.8, 110.4, 104.4, 101.9, 100.1, 81.0, 79.3, 
79.2, 78.4, 77.0, 74.8, 73.5, 69.0, 68.9, 67.3, 55.6, 38.6, 36.9, 28.1, 26.3, 18.6, 16.6, 14.6, 
14.2, 12.3; IR (film): ν~  = 3474, 3072, 2935, 2873, 1718, 1651, 1589, 1518, 1381, 1252, 
1175, 1075, 1036, 990, 923, 829; MS (EI): m/z (%): 43 (17), 55 (65), 57 (11), 59 (13), 83 
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(100), 97 (12), 99 (63), 100 (33), 121 (13), 135 (20), 136 
(26), 137 (32), 179 (13), 363 (24), 549 (20); HRMS (EI): 















Analytical and spectroscopic data of the regioisomer: m.p. = 
67-68 °C. [ ]20Dα  = –7.0 (c = 0.83, CH2Cl2); 1H NMR (400 
MHz, CD2Cl2): δ = 7.39 (d, J = 8.8 Hz, 2 H), 6.96 (m, 1 H), 
6.89 (d, J = 8.8 Hz, 2 H), 5.90 (ddt, J = 17.2, 10.2, 7.1 Hz, 1 
H), 5.51 (s, 1 H), 5.09-5.01 (m, 3 H), 4.91-4.87 (m, 1 H), 
4.31 (dd, J = 10.4, 5.0 Hz, 1 H), 4.25 (d, J = 7.9 Hz, 1 H), 4.00-3.86 (m, 3 H), 3.81-3.71 (m, 4 
H), 3.65-3.57 (m, 3 H), 3.48-3.40 (m, 2 H), 2.73 (d, J = 3.8 Hz, 1 H), 2.27 (m, 2 H), 1.86 (m, 
3 H), 1.81 (m, 3 H), 1.51-1.29 (m, 13 H), 0.89 (t, J = 7.2 Hz, 3 H); 13C NMR (100 MHz, 
CD2Cl2): δ = 167.6, 160.6, 138.6, 135.7, 130.2, 128.6, 127.9, 116.8, 113.9, 109.9, 102.1, 
100.3, 100.2, 81.3, 79.8, 79.3, 78.8, 76.8, 75.3, 73.1, 69.1, 68.8, 66.5, 55.6, 38.9, 37.1, 28.0, 













ν~  = 3494, 3074, 2935, 2872, 1722, 1651, 1616, 
1589, 1519, 1303, 1174, 921, 830; MS (EI): m/z (%): 549 (8), 363 (98), 219 (19), 209 (12), 
179 (19), 137 (18), 136 (18), 135 (16), 100 (24), 99 (41), 83 (100), 55 (28); HRMS (ESI): 
m/z: calcd for C35H50O12Na [M+ + Na]: 685.31945, found: 685.31954. 
 
Compound 18b (n = 3): Prepared analogously from compound 17b (200 mg, 0.329 mmol) as 
a colorless solid (167 mg, 73 %). [ ]20Dα  = −20.7 (c = 0.73, CHCl3); 1H NMR (300 MHz, 
C6D6): δ = 7.49 (m, 2 H), 7.00 (qq, J = 7.0, 1.5 Hz, 1 H), 6.69 (m, 2 H), 6.14 (m, 1 H), 5.71 (t, 
J = 9.4 Hz, 1 H), 5.26 (s, 1 H), 5.15 (d, J = 5.1 Hz, 1 H), 5.11 (s, 1 H), 4.82 (d, J = 7.5 Hz, 1 
H), 4.82 (d, J = 7.5 Hz, 1 H), 4.31 (dd, J = 10.2, 4.9 Hz, 1 H), 4.24 (d, J = 4.2 Hz, 1 H), 3.96-
4.03 (m, 1 H), 3.80 (br s, 1 H), 3.69-3.80 (m, 2 H), 3.63 (t, J = 10.6 Hz, 1 H), 3.58 (d, J = 12.3 
Hz, 1 H), 3.48 (dd, J = 5.3, 2.1 Hz, 1 H), 3.37 (dd, J = 9.7, 4.8 Hz, 1 H), 3.21 (s, 3 H), 3.18 
(dd, J = 6.4, 2.1 Hz, 2 H), 1.77 (t, J = 1.2 Hz, 3 H), 1.66-1.74 (m, 1 H), 1.45-1.62 (m, 4 H), 
1.39 (s, 3 H), 1.31 (t, J = 6.5 Hz, 10 H), 1.15 (s, 3 H), 0.89 (t, J = 7.5 Hz, 3 H); 13C NMR (75 
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MHz, C6D6): δ = 168.1, 161.1, 138.0, 136.4, 131.1, 129.6, 117.5, 114.4, 110.8, 105.6, 102.4, 
101.4, 81.8, 80.0, 79.9, 79.6, 77.3, 76.2, 74.6, 69.5, 69.1, 67.8, 55.3, 38.8, 35.6, 32.8, 28.5, 
26.9, 25.8, 23.6, 17.4, 14.9, 14.6, 12.9; IR (film): ν~  = 3452, 3328, 3078, 3068, 2980, 2932, 
2873, 2856, 1717, 1616, 1573, 1518, 1462, 1379, 1302, 1248, 1173, 1137, 1070, 1031, 921, 
867, 827, 787, 729, 687; HRMS (EI): m/z: calcd for C37H55O12 [M+ + H]: 691.3688, found: 
631.3693. 
 
Compound 19a: TBSOTf (87.0 mL, 0.30 mmol) was added to a solution of compound 18a 
(100 mg, 0.15 mmol) and 2,6-lutidine (69.0 mL, 0.75 mmol) in CH2Cl2 (2 mL) and the 
resulting mixture was stirred for 2 h. Evaporation of the solvent followed by purification of 
the residue by preparative TLC (hexanes/EtOAc, 4/1) gave product 19a as a colorless solid 
(112 mg, 96 %). M.p. = 54-55 °C. [ ]20Dα  = –11.7 (c = 0.72, CH2Cl2); 1H NMR (400 MHz, 
CD2Cl2): δ = 7.20 (d, J = 8.8 Hz, 2 H), 6.78 (m, 1 H), 6.75 (d, J = 8.8 Hz, 2 H), 5.80 (ddt, J = 
17.2, 10.2, 7.0 Hz, 1 H), 5.34 (s, 1 H), 5.15 (m, 1 H), 5.00-4.93 (m, 3 H), 4.21-4.17 (m, 2 H), 
4.06 (dd, J = 6.8, 5.7 Hz, H), 3.89 (dd, J = 5.5, 2.0 Hz, 1 H), 3.73-3.66 (m, 6 H), 3.59-3.50 
(m, 3 H), 3.43-3.39 (m, 1 H), 2.18 (m, 2 H), 1.71-1.66 (m, 6 H), 1.43-1.19 (m, 13 H), 0.80 (t, 
J = 5.0 Hz, 3 H), 0.73 (s, 9 H), −0.02 (s, 3 H), −0.11 (s, 3 H); 13C NMR (100 MHz, CD2Cl2): 
δ = 167.2, 160.5, 138.1, 135.6, 130.3, 128.8, 127.7, 116.8, 113.8, 110.0, 101.6, 100.6, 100.0, 
80.0, 79.6, 78.4, 77.0, 76.2, 74.8, 74.3, 69.1, 68.9, 66.5, 55.6, 38.8, 36.9, 28.0, 26.4, 25.9, 
18.8, 18.3, 16.7, 14.5, 14.2, 12.3, –3.6, –4.8; IR (KBr): ν~  = 3073, 2958, 2934, 2859, 1724, 
1653, 1616, 1519, 1252, 1181, 1085, 923, 837, 779, 671; MS (EI): m/z (%): 719 (10), 663 
(12), 477 (7), 283 (13), 211 (18), 183 (18), 179 (21), 158 (10), 157 (79), 136 (17), 135 (13), 
121 (35), 99 (23), 97 (19), 83 (100), 73 (29), 59 (14), 55 (79), 43 (14); HRMS (ESI): m/z: 
calcd for C41H64O12SiNa [M+ + Na]: 799.40593, found: 799.40524. 
 
Compound 19b (n = 3): Prepared analogously as a colorless syrup (143 mg, 93 %). 1H NMR 
(400 MHz, C6D6): δ = 7.46 (m, 2 H), 7.01 (qq, J = 7.0, 1.3 Hz, 1 H), 6.65 (m, 2 H), 6.18 (m, 1 
H), 5.75 (dd, J = 9.6, 8.6 Hz, 1 H), 5.28 (s, 1 H), 5.19 (d, J = 7.3 Hz, 2 H), 5.16 (s, 1 H), 4.44 
(d, J = 7.3 Hz, 1 H), 4.20-4.28 (m, 2 H), 4.15 (dd, J = 10.2, 4.9 Hz, 1 H), 3.94 (dd, J = 8.3, 7.3 
 20
Hz, 1 H), 3.82 (quint., J = 5.7 Hz, 1 H), 3.52-3.60 (m, 3 H), 3.38-3.44 (m, 1 H), 3.33 (qq, J = 
6.5, 1.9 Hz, 1 H), 3.19 (s, 3 H), 2.44-2.48 (m, 2 H), 1.85 (s, 3 H), 1.64-1.75 (m, 1 H), 1.47-
1.62 (m, 4 H), 1.39 (dd, J = 7.1, 1.3 Hz, 3 H), 1.36 (d, J = 6.6 Hz, 3 H), 1.33 (s, 3 H), 1.24-
1.30 (m, 4 H), 1.22 (s, 3 H), 1.06 (s, 9 H), 0.89 (s, 1 H), 0.52 (br s, 1 H), 0.34 (s, 3 H), 0.26 (s, 
3H); 13C NMR (100 MHz, C6D6): δ = 176.4, 167.3, 161.0, 137.8, 136.5, 131.2, 129.9, 117.4, 
114.3, 110.4, 102.3, 101.4, 101.0, 80.7, 80.2, 79.9, 79.0, 77.4, 76.4, 75.7, 75.6, 69.5, 69.4, 
67.0, 55.2, 39.8, 35.6, 32.8, 28.4, 27.1, 26.7, 26.6, 26.5, 25.8, 23.6, 19.0, 17.5, 14.9, 14.6, 
13.0, −2.8, −3.9; IR (film): ν~  = 3072, 2955, 2931, 2858, 1721, 1650, 1616, 1519, 1463, 1379, 
1303, 1248, 1221, 1173, 1072, 1034, 1003, 923, 855, 834, 778, 728, 671; HRMS (ESI): m/z: 
calcd for C43H68O12SiNa [M+ + Na]: 827.4372, found: 827.4372.  
 
Compounds 20a and 21a (n = 1): Disaccharide 19a (500 mg, 0.643 mmol) was added to a 
suspension of freshly activated MS 4 Å (1.7 g) in CH3CN (15 mL) and the resulting mixture 
was stirred for 15 min at that temperature. NaBH3CN (404 mg, 6.43 mmol) was then 
introduced before the suspension was cooled to 0 °C and TMSCl (0.82 mL, 6.43 mmol) was 
added. The mixture was quickly warmed to room temperature and stirring was continued for 3 
h. The suspension was filtered through Celite, the filtrate diluted with Et2O, the organic phase 
washed with sat. aq. NaHCO3, dried over sodium sulfate, filtered and evaporated. The residue 
was purified by flash chromatography to give a mixture of the reduction products (308 mg, 
62 %, 21a/20a = 3.5/1). This mixture does not need to be further purified because compound 
27 derived thereof can be isolated in pure form by conventional chromatography at the next 
step (see below). For analytical purposes, however, the regioisomers were separated by 
preparative HPLC (Nucleodur 100-16-C18/A; MeOH/H2O = 4/1; flow rate: 35.0 mL/min; 
pressure: 4.1 MPa) to give product 21a (210 mg, 42 %) and regioisomer 20a (24 mg, 5 %), 
which showed the following spectroscopic and analytical properties:  
Compound 21a: 1H NMR (400 MHz, CD2Cl2): δ = 7.28 (d, J = 8.7 
Hz, 2 H), 6.92 (m, 1 H), 6.87 (d, J = 8.7 Hz, 2 H), 5.90 (ddt, J = 
17.2, 10.2, 7.1 Hz, 1 H), 5.09-4.99 (m, 3 H), 4.93 (d, J = 7.7 Hz, 1 













J = 8.1 Hz, 1 H), 4.14 (m, 1 H), 3.98 (dd, J = 5.6, 2.0 Hz, 1 H), 3.85-3.40 (m, 11 H), 2.75 (br 
s, 1 H), 2.28 (m, 2 H), 1.84-1.71 (m, 6 H), 1.55-1.31 (m, 13 H), 0.89 (t, J = 7.2 Hz, 3 H), 0.81 
(s, 9 H), 0.07 (s, 3 H), –0.02 (s, 3 H); 13C NMR (100 MHz, CD2Cl2): δ = 168.6, 159.7, 138.7, 
135.7, 130.4, 129.9, 128.7, 116.8, 114.0, 110.0, 100.1, 99.9, 80.2, 79.3, 78.4, 77.0, 75.9, 74.7, 
73.6, 73.3, 71.2, 69.5, 68.9, 55.6, 38.8, 36.9, 28.0, 26.5, 25.9, 18.8, 18.3, 16.8, 14.5, 14.1, 
12.2, –3.5, –4.9. HRMS (ESI): m/z: calcd for C41H66O12SiNa [M+ + Na]: 801.42158, found: 
801.42204.  
.8, 69.0, 62.0, 55.5, 38.8, 36.9, 28.1, 
6.3, 25.8, 18.7, 18.2, 16.7, 14.6, 14.1, 12.3, –3.6, –4.8. 
 H-6,6’ (m, 2 H) in 20a and H-4 (app. t, 1 H) in 21a showed the 
xpected acylation shifts. 
Compound 20a: 1H NMR (400 MHz, CD2Cl2): δ = 7.13 (d, J = 8.8 
Hz, 2 H), 6.90 (m, 1 H), 6.82 (d, J = 8.8 Hz, 2 H), 5.91 (ddt, 1 = 
17.2, 10.2, 7.1 Hz, 1 H), 5.22 (t, J = 9.2 Hz, 1 H), 5.11-5.03 (m, 2 
H), 4.95 (d, J = 7.6 Hz, 1 H), 4.45 (m, 2 H), 4.29 (d, J = 8.1 Hz, 1 
H), 4.15 (dd, J = 6.8, 5.7 H, 1 H), 3.98 (dd, J = 5.6, 2.1 Hz, 1 H), 
3.84-3.76 (m, 6 H), 3.71-3.65 (m, 2 H), 3.61 (t, J = 9.5 Hz, 1 H), 3.52 (dd, J = 9.0, 7.5 Hz, 1 
H), 3.42-3.38 (m, 1 H), 2.28 (m, 2 H), 1.84-1.79 (m, 6 H), 1.65 (br s, 1 H), 1.55-1.32 (m, 13 
H), 0.09 (t, J = 7.2 Hz, 3 H), 0.82 (s, 9 H), 0.07 (s, 3 H), –0.03 (s, 3 H); 13C NMR (100 MHz, 
CD2Cl2): δ = 167.1, 159.7, 138.26, 135.6, 130.5, 130.1, 129.0, 116.8, 114.0, 110.0, 100.2, 




















Compound 27: Et3N (43 μL, 0.305 mmol) and 2,4,6-trichlorobenzoyl chloride (22 mL, 0.139 
mmol) were added to a solution of acid 26 (39 mg, 0.139 mmol) in toluene (0.6 mL) and the 
resulting mixture was stirred for 1.5 h before a solution of the mixture of alcohols 21a and 
20a (54 mg, 0.0693 mmol) and DMAP (8.0 mg, 0.0693 mmol) in CH2Cl2 (0.5 mL) was 
introduced. Stirring was continued for 3 h before the mixture was filtered through a pad of 
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silica. The filtrate was evaporated and the residue purified by flash chromatography 
(hexanes/EtOAc, 6/1) to give product 27 as a colorless oil (56.8 mg, 79 %). [ ]20Dα  = –4.4 (c = 
0.5, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 7.49-7.46 (m, 2 H), 7.26-7.18 (m, 10 H), 6.97-
6.94 (m, 2 H), 6.84-6.80 (m, 3 H), 6.31 (s, 1 H), 5.94 (ddt, J = 17.2, 10.2, 7.1 Hz, 1 H), 5.27 
(t, J = 9.4 Hz, 1 H), 5.08-4.99 (m, 3 H), 4.90 (d, J = 7.6 Hz, 1 H), 4.41 (d, J = 11.6 Hz, 1 H), 
4.39 (d, J = 11.6 Hz, 1 H), 4.31 (d, J = 7.7 Hz, 1 H), 4.15 (t, J = 6.1 Hz, 1 H), 3.97-3.90 (m, 2 
H), 3.78-3.74 (m, 4 H), 3.66-3.53 (m, 3 H), 3.36-3.34 (m, 2 H), 2.29-2.26 (m, 2 H), 1.76-1.75 
(m, 6 H), 1.56-1.24 (m, 11 H), 0.86 (t, J = 7.2 Hz, 3 H), 0.81 (s, 9 H), 0.41 (s, 3 H), 0.26 (s, 3 
H), 0.04 (s, 3 H), –0.06 (s, 3 H); 13C NMR (100 MHz, CDCl3): δ = 166.9, 165.8, 164.8, 159.0, 
144.7, 138.3, 137.9, 135.4, 133.9, 132.9, 130.3, 129.4, 128.6, 128.3, 127.8, 127.4, 126.8, 
126.6, 116.5, 113.6, 109.7, 100.2, 99.8, 79.6, 78.7, 76.4, 76.0, 75.3, 73.6, 73.3, 73.1, 69.9, 
68.5, 68.4, 55.2, 38.5, 36.6, 27.7, 26.3, 25.7, 18.3, 18.0, 16.7, 14.3, 14.1, 12.0, –0.8, –1.5, –
3.9, –5.0; IR (film): ν~  = 3070, 2956, 2932, 2904, 2858, 1730, 1652, 1612, 1587, 1513, 1248, 
1160, 1074, 915, 839, 780, 701; MS (EI): m/z (%): 83 (14), 121 (100), 157 (9), 265 (30), 565 
(4), 985 (2); HRMS (ESI): m/z: calcd for C58H82O13Si2Na [M+ + Na]: 1065.51862, found: 
065.51779. 




Compound 54: A solution of disaccharide 19 (138 mg, 0.171 mmol) in MeCN (1 mL) was 
added to a suspension of freshly activated MS 4 Å (466 mg) in MeCN (2.5 mL) and the 
resulting mixture was stirred for 10 min before NaBH3CN (108 mg, 1.71 mmol) was 
introduced. The resulting suspension was stirred at 0 °C for 5 min before TMSCl (220 μL, 
1.71 mmol) was added. Immediately after the addition, the mixture was warmed to room 
temperature and stirring was continued for 1.5 h. The suspension was filtered through Celite, 
the filtrate was diluted with Et2O, the organic phase was washed with sat. aq. NaHCO3, dried 





NEt3 (53 μL, 0.381 mmol) and 2,4,6-trichlorobenzoyl chloride (27 μL, 0.173 mmol) were 
added to a solution of acid 26 (49 mg, 0.173 mmol) in toluene (770 μL) and the mixture was 
stirred for 1.5 h before a solution of the isomeric alcohols 20b and 21b (70 mg, 0.0867 mmol) 
in CH2Cl2 (650 μL) and DMAP (10.6 mg, 0.0867 mmol) were successively added. Stirring 
was continued for 14 h before the mixture was filtered through a pad of silica which was 
carefully rinsed with EtOAc. The combined filtrates was evaporated and the residue purified 
by flash chromatography (hexanes/EtOAc, 12.1) to give product 54 as a colorless oil (67 mg, 
72 %); 1H NMR (400 MHz, CDCl3): δ = 7.49-7.46 (m, 2 H), 7.25-7.20 (m, 10 H), 6.97-6.95 
(m, 2 H), 6.84-6.82 (m, 3 H), 6.31 (s, 1 H), 5.99-5.92 (m, 1 H), 5.27 (t, J = 9.4 Hz, 1 H), 5.08-
5.00 (m, 3 H), 4.91 (d, J = 7.6 Hz, 1 H), 4.41 (q, J = 11.6 Hz, 2 H), 4.31 (d, J = 7.7 Hz, 1 H), 
4.16 (t, J = 6.1 Hz, 1 H), 3.97-3.91 (m, 2 H), 3.78-375 (m, 4 H), 3.65-3.53 (m, 3 H), 3.36-3.35 
(m, 2 H), 2.30-2.27 (m, 2 H), 1.76-1.75 (m, 6 H), 1.54-1.24 (m, 15 H), 0.87 (t, J = 7.2 Hz, 3 
H), 0.81 (s, 9 H), 0.42 (s, 3 H), 0.26 (s, 3 H), 0.05 (s, 3 H), −0.05 (s, 3 H); 13C NMR (100 
MHz, CDCl3): δ = 166.9, 165.8, 164.8, 159.0, 144.7, 138.3, 137.7, 135.4, 134.0, 132.8, 130.2, 
129.4, 128.6, 127.7, 127.4, 126.7, 126.5, 116.5, 113.5, 109.7, 100.3, 99.7, 79.6, 78.7, 76.3, 
76.0, 75.4, 73.6, 73.3, 73.1, 69.9, 68.5, 68.4, 55.3, 38.5, 36.5, 32.1, 27.7, 26.3, 25.7, 24.7, 
22.7, 18.0, 16.6, 14.3, 14.1, 12.0, −0.8, −1.5, −3.8, −5.0; IR (film): ν~  = 2934, 2858, 1731, 
651, 1613, 1588, 1514, 1246, 1160, 1069, 921, 838, 778; HRMS (ESI): m/z: calcd for 
evaporated and the residue was purified by flash chromatography 
exanes/EtOAc, 6/1) to give alcohol 28 (150 mg) which contained p-methoxybenzaldehyde 
1
C60H86O13Si2Na [M+ + Na]: 1093.5507, found: 1093.5499. 
 
Synthesis of 29: DDQ (49.0 mg, 0.216 mmol) was added to a solution of compound 27 (150 
mg, 0.144 mmol) in CH2Cl2 (6.0 mL) and water (0.3 mL). The mixture was stirred for 16 h 
before it was filtered through a pad of silica which was carefully rinsed with ethyl acetate. 
The combined filtrates were 
(h
as an inseparable impurity.  
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Et3N (45 μL, 0.318 mmol) and 2,4,6-trichlorobenzoyl chloride (23 μL, 0.148 mmol) were 
added to a solution of 4-oxo-8-nonenoic acid (25 mg, 0.0862 mmol)6,7 in toluene (1.0 mL) 
and the mixture was stirred for 1.5 h before a solution of the crude alcohol 28 (75 mg, ca. 
0.074 mmol) and DMAP (9.0 mg, 0.074 mmol) in toluene (1.5 mL) was introduced. Stirring 
was continued for 2 h, the mixture was passed through a pad of silica which was carefully 
rinsed with EtOAc, the combined filtrates were evaporated, and the residue was purified by 
flash chromatography (hexanes/EtOAc, 8/1) to give disaccharide 29 as a colorless syrup (61.7 
mg, 78 %). [ ]20Dα  = –4.2 (c = 0.43, CH2Cl2); 1H NMR (400 MHz, CDCl3): δ = 7.47-7.44 (m, 2 
H), 7.28-7.18 (m, 6 H), 6.98-6.95 (m, 2 H), 6.81 (m, 1 H), 6.33 (s, 1 H), 5.93 (ddt, J = 17.1, 
10.1, 7.1 Hz, 1 H), 5.77 (ddt, J = 17.0, 10.3, 6.4 Hz, 1 H), 5.27 (t, J = 9.4 Hz, 1 H), 5.08-4.96 
(m, 5 H), 4.94 (d, J = 7.6 Hz, 1 H), 4.28 (d, J = 7.8 Hz, 1 H), 4.14 (t, J = 5.9 Hz, 1 H), 4.01-
3.99 (m, 2 H), 3.97 (dd, J = 5.6, 2.0 Hz, 1 H), 3.89-3.85 (m, 1 H), 3.77 (m, 1 H), 3.68-3.61 
(m, 2 H), 3.55 (dd, J = 9.1, 7.6 Hz, 1 H), 2.67-2.42 (m, 6 H), 2.27 (m, 2 H), 2.09-2.03 (m, 2 
H), 1.77-1.75 (m, 6 H), 1.59-1.34 (m, 15 H), 0.89 (t, J = 7.2 Hz, 3 H), 0.81 (s, 9 H), 0.39 (s, 3 
H), 0.27 (s, 3 H), 0.04 (s, 3 H), –0.06 (s, 3 H); 13C NMR (100 MHz, CDCl3): δ = 208.6, 172.4, 
166.9, 166.6, 164.7, 144.7, 138.2, 138.0, 135.4, 133.8, 132.6, 128.7, 128.2, 127.9, 127.6, 
126.9, 126.6, 116.5, 115.3, 109.7, 100.3, 99.8, 79.7, 79.1, 77.2, 76.5, 76.0, 75.2, 73.2, 71.5, 
69.4, 68.6, 63.0, 41.9, 38.6, 37.1, 36.7, 33.1, 28.0, 27.8, 26.4, 25.7, 22.8, 18.3, 18.0, 16.7, 
14.4, 14.1, 12.1, −0.7, –1.4, –3.8, –4.9; IR (film): ν~  = 3071, 2956, 2933, 1732, 1651, 1588, 
1248, 1157, 914, 839, 780, 730, 701; MS (EI): m/z (%): 83 (68), 157 (29), 265 (100), 393 
0), 775 (9), 793 (42), 961 (13), 1017 (7); HRMS (ESI): m/z: calcd for C59H86O14Si2Na [M+ + (3
Na]: 1097.54483, found: 1097.54416. 
 
Diene 35: Prepared analogously from 8-nonenoic acid (33 mg, 0.212 mmol) and crude 
alcohol 28 (112 mg, 0.106 mmol) as a colorless syrup (81 mg, 72 %). [ ]20Dα  = –10.8 (c = 0.32, 
                                                 
V. Thuy, H. Petit, J. P. Célérier, Synth. Commun. 1996, 26, 3897-3901. It was found that the reaction is 
cleaner in the presence of Fe(acac)  (10 mol%) in THF at −78 °C, even though the unoptimized yield was only 
6 Prepared by reaction of 4-pentenylmagnesium bromide with succinic anhydride, cf. G. Lhommet, S. Fréville, 
3
41 %. For iron catalyzed formations of functionalized ketones, see: B. Scheiper, M. Bonnekessel, H. Krause, 
A. Fürstner, J. Org. Chem. 2004, 69, 3943-3949. 
7 D. M. Hodgson, P. A. Stupple, F. Y. T. M. Pierard, A. H. Labande, C. Johnstone, Chem. Eur. J. 2001, 7, 4465-
4476. 
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CH2Cl2); 1H NMR (400 MHz, CD2Cl2): δ =  7.48-7.45 (m, 2 H), 7.29-7.19 (m, 6 H), 6.99-
6.97 (m, 2 H), 6.82 (m, 1 H), 5.90 (ddt, J = 17.2, 10.2, 6.8 Hz, 1 H), 5.82 (ddt, J = 17.2, 10.2, 
6.8 Hz, 1 H), 5.25 (t, J = 9.3 Hz, 1 H), 5.10-4.91 (m, 6 H), 4.30 (d, J = 8.1 Hz, 1 H), 4.16-3.98 
(m, 4 H), 3.82-3.77 (m, 2 H), 3.71-3.66 (m, 2 H), 3.60 (dd, J = 9.0, 7.8 Hz, 1 H), 2.30-2.25 
(m, 4 H), 2.07-2.02 (m, 2 H), 1.78-1.75 (m, 6 H), 1.61-1.29 (m, 22 H), 0.90 (t, J = 7.3 Hz, 3 
H), 0.81 (s, 9 H), 0.36 (s, 3 H), 0.29 (s, 3 H), 0.07 (s, 3 H), –0.04 (s, 3 H); 13C N R (100 
MHz, CD2Cl2): δ = 173.5, 167.1, 166.8, 165.0, 145.1, 139.6, 138.7, 138.7, 135.6, 134.2, 
133.0, 129.0, 128.9, 128.6, 128.2, 127.8, 127.2, 126.9, 116.8, 114.3, 110.0, 100.1, 80.2, 78.6, 
77.1, 76.4, 75.7, 73.5, 72.1, 69.5, 69.0, 62.6, 38.8, 36.9, 34.2, 34.1, 29.4, 29.2, 29.1, 28.2, 
26.4, 25.8, 25.0, 18.8, 18.2, 16.7, 
M
14.6, 14.2, 12.2, –0.7, –1.1, –3.6, –4.8; IR (film): ν~
xture was stirred 
 = 2930, 
858, 1732, 1580, 1428, 1380, 1320, 1247, 1221, 1152, 1111, 1072, 1038, 911, 885, 837, 778, 
L), and the resulting mi
t ambient temperature for 16 h. The suspension was then filtered through a pad of silica 
mg, 
2
730, 699; MS (EI): m/z (%): 83 (84), 99 (13), 157 (34), 211 (10), 265 (100), 379 (25), 761 (8), 
779 (53), 947 (20), 1003 (12); HRMS (ESI): m/z: calcd for C59H88O13Si2Na [M+ + Na]: 
1083.56557, found: 1083.56558. 
 
Diene 45: DDQ (19.0 mg, 0.0830 mmol) was added to a solution of compound 27 (57.7 mg, 
0.0553 mmol) in CH2Cl2 (2.0 mL) and water (0.1 m
a
which was rinsed with ethyl acetate, the combined filtrates were evaporated, and the residue 
was purified by flash chromatography (hexanes/EtOAc, 6/1) to give alcohol 28 (45.6 mg) 
which contained traces of p-methoxybenzaldehyde. 
 
Et3N (26 μL, 0.185 mmol) and 2,4,6-trichlorobenzoyl chloride (13 mL, 0.0862 mmol) were 
added to a solution of acid 44 (19.7 mg, 0.0862 mmol) in toluene (0.5 mL). After stirring for 
1.5 h at ambient temperature, a solution of the crude alcohol 28 (45.6 mg) and DMAP (5.0 
0.0431 mmol) in toluene (1.0 mL) was introduced and stirring continued for 2 h. The 
mixture was filtered through a pad of silica which was carefully rinsed with EtOAc, the 
combined filtrates were evaporated and the residue was purified by flash chromatography 
(hexanes/EtOAc, 8/1) to give product 45 as a colorless syrup (54.6 mg, 87 % over both steps). 
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[ ]20Dα  = –3.7 (c = 0.40, CH2Cl2); 1H NMR (400 MHz, CD2Cl2): δ = 7.47-7.45 (m, 2 H), 7.29-
7.19 (m, 6 H), 7.00-6.97 (m, 2 H), 6.82 (m, 1 H), 6.33 (s, 1 H), 5.89 (ddt, J = 17.2, 10.2, 6.9 
Hz, 1 H), 5.81 (ddt, J = 17.0, 10.3, 6.6 Hz, 1 H), 5.25 (t, J = 9.4 Hz, 1 H), 5.10-4.99 (m, 7 H), 
4.30 (d, J = 8.1 Hz, 1 H), 4.16-4.03 (m, 3 H), 3.99 (dd, J = 5.5, 1.9 Hz, 1 H), 3.82-3.65 (m, 4 
H), 3.60 (m, 1 H), 2.83-2.47 (m, 4 H), 2.28 (m, 2 H), 2.18-2.11 (m, 5 H), 1.96-1.74 (m, 8 H), 
1.55-1.32 (m, 13 H), 0.90 (t, J = 7.2 Hz, 3 H), 0.81 (s, 9 H), 0.37 (s, 3 H), 0.28 (s, 3 H), 0.07 
(s, 3 H), –0.04 (s, 3 H); 13C NMR (100 MHz, CD2Cl2): δ = 205.8, 172.4, 170. 7, 167.1, 166.9, 
165.0, 145.1, 138.7, 137.5, 135.6, 134.2, 133.0, 129.0, 128.5, 128.2, 127.9, 127.2, 126.9, 
116.8, 115.9, 110.0, 100.1, 100.0, 80.2, 78.6, 78.0, 77.1, 76.4, 75.6, 73.5, 72.0, 69.6, 69.0, 
63.1, 38.8, 36.9, 33.7, 33.6, 30.1, 29.6, 28.2, 27.5, 26.4, 25.8, 20.8, 18.8, 18.2, 16.7, 14.6, 
12.2, –0.7, −1.2, –3.6, –4.8; IR (film): 14.2, ν~  = 3072, 2956, 2932, 2858, 1732, 1651, 1642, 
1586, 1428, 1248, 1113, 916, 839, 780; MS (EI): m/z (%): 83 (63), 157 (29), 265 (100), 265 
(100), 451 (32), 833 (10), 851 (49), 1019 (17), 1075 (8); HRMS (ESI): m/z: calcd for 
C61H88O16Si2Na [M+ + Na]: 1155.55032, found: 1155.54897. 
 
Diene 50: Prepared analogously from carboxylic acid 49 (100 mg, 0.33 mmol) and crude 
alcohol 28 (231 mg, 0.25 mmol) as a colorless syrup (220 mg, 73 %). [ ]20Dα  = –6.2 (c = 1.01, 
CH2Cl2). 1H NMR (400 MHz, CD2Cl2): δ =  7.47-7.45 (m, 2 H), 7.30-7.19 (m, 9 H), 6.99-
6.92 (m, 3 H), 6.88 (m, 1 H), 6.33 (s, 1 H), 5.91 (ddt, J = 17.2, 10.2, 7.0 Hz, 1 H), 5.79 (ddt, 
J = 17.0, 10.3, 6.6 Hz, 1 H), 5.26 (t, J = 9.3 Hz, 1 H), 5.10-4.96 (m, 6 H), 4.54 (d, J = 11.1 
Hz, 1 H), 4.35 (d, J = 11.1 Hz, 1 H), 4.31 (d, J = 8.1 Hz, 1 H), 4.16 (dd, J = 6.4, 5.9 Hz, 1 H), 
4.08-4.05 (m, 2 H), 3.99 (dd, J = 5.6, 1.9 Hz, 1 H), 3.86-3.78 (m, 6 H), 3.73-3.66 (m, 2 H), 
3.61 (dd, J = 9.0, 7.8 Hz, 1 H), 2.91-2.51 (m, 4 H), 2.31-2.28 (m, 2 H), 2.21-2.09 (m, 2 H), 
1.77-1.33 (m, 21 H), 0.91 (t, J = 7.2 Hz, 3 H), 0.82 (s, 9 H), 0.37 (s, 3 H), 0.29 (s, 3 H), 0.08 
(s, 3 H), –0.03 (s, 3 H); 13C NMR (100 MHz, CD2Cl2): δ = 211.0, 172.7, 167.2, 166.9, 165.1, 
159.9, 145.2, 138.7, 138.6, 138.2, 135.7, 134.2, 133.0, 130.4, 130.0, 129.0, 128.6, 128.2, 
127.9, 127.2, 127.0, 116.8, 115.5, 114.2, 110.1, 100.2, 100.1, 84.1, 80.2, 78.7, 77.1, 76.5, 
75.7, 73.5, 72.4, 72.1, 69.7, 69.0, 63.2, 55.6, 38.9, 37.0, 33.1, 31.9, 29.8, 28.3, 27.6, 26.5, 
ilm): ν~  25.9, 18.8, 18.3, 16.8, 14.6, 14.2, 12.2, –0.7, –1.1, –3.6, –4.8; IR (f = 3072, 2955, 
 27
2933, 2858, 1731, 1514, 1249, 1156, 1112, 1074, 1039, 915, 839, 818, 780, 730, 701; MS 
(EI): m/z (%): 83 (42), 121 (100), 157 (19), 211 (6), 265 (71), 529 (10), 911 (2), 929 (8), 1097 
(3); HRMS (ESI): m/z: calcd for C67H94O16Si2Na [M+ + Na]: 1233.59726, found: 1233.59623. 
 
Compound 56: Prepared analogously as a colorless oil (72 mg, 83 % over both steps). 1H 
NMR (400 MHz, CDCl3): δ = 47-7.45 (m, 2 H), 7.27-7.20 (m, 6 H), 6.98-6.96 (m, 2 H), 6.82-
6.81 (m, 1 H), 6.33 (s, 1 H), 5.99-5.89 (m, 1 H), 5.82-5.72 (m, 1 H), 5.28 (t, J = 9.4 Hz, 1 H), 
5.09-4.96 (m, 5 H), 4.94 (d, J = 7.6 Hz, 1 H), 4.28 (d, J = 7.8 Hz, 1 H), 4.15 (t, J = 5.9 Hz, 1 
H), 4.01-3.99 (m, 2 H), 3.97 (dd, J = 5.6, 2.0 Hz, 1 H), 3.89-3.86 (m, 1 H), 3.80-3.75 (m, 1 
H), 3.69-3.60 (m, 2 H), 3.55 (dd, J = 9.1, 7.6 Hz, 1 H), 2.69-2.42 (m, 6 H), 2.29-2.26 (m, 2 
H), 2.09-2.03 (m, 2 H), 1.77-1.75 (m, 6 H), 1.71-1.31 (m, 19 H), 0.89 (t, J = 7.2 Hz, 3 H), 
0.81 (s, 9 H), 0.39 (s, 3 H), 0.28 (s, 3 H), 0.05 (s, 3 H), −0.05 (s, 3 H); 13C NMR (100 MHz, 
CDCl3): δ = 208.7, 172.3, 166.8, 166.5, 164.8, 144.7, 138.1, 137.9, 135.4, 133.8, 132.5, 
128.6, 128.1, 127.8, 127.5, 126.8, 126.5, 116.4, 115.3, 109.8, 100.4, 99.8, 79.7, 79.6, 77.2, 
76.4, 76.0, 75.2, 73.3, 71.5, 69.5, 68.5, 63.0, 41.8, 38.5, 37.2, 34.5, 33.2, 31.8, 28.0, 27.7, 
6.3, 25.6, 24.7, 22.7, 22.6, 18.0, 16.7, 14.3, 14.1, 12.0, −0.6, −1.4, −3.8, −4.9; IR (film): ν~2  = 
320, 1247, 1153, 1111, 1073, 1039, 913, 838, 
on of diene 29 (60 
g, 0.0558 mmol) in CH2Cl2 (10 mL) and the resulting mixture was stirred under reflux for 4 
2930, 2857, 1731, 1651, 1588, 1428, 1380, 1




Compound 32: Complex 30 (5.0 mg, 0.00558 mmol) was added to a soluti
m
h before the reaction was quenched with ethyl vinyl ether. Evaporation of all volatile 
materials followed by flash chromatography of the residue (hexanes/EtOAc, 4/1) gave the 
corresponding metathesis product 31 as a mixture of (E)- and (Z)-isomers.  
 
A solution of cycloalkene 31 (42 mg, 0.0398 mmol) and RhCl(PPh3)3 (7.0 mg, 0.0076 mmol) 
in EtOH (0.6 mL) was stirred under an atmosphere of H2 (1 atm) overnight. Evaporation of 
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the solvent and flash chromatography of the crude product (hexanes/EtOAc, 4/1) gave 
compound 32 as a colorless oil (34 mg, 81 %). [ ]20Dα  = +0.6 (c = 0.50, CH2Cl2); 1H NMR (400 
MHz, CDCl3): δ = 7.46-7.45 (m, 2 H), 7.28-7.17 (m, 6 H), 6.97-6.95 (m, 2 H), 6.86 (m, 1 H), 
6.31 (s, 1 H), 5.27 (t, J = 9.3 Hz, 1 H), 5.08 (t, J = 9.8 Hz, 1 H), 4.93 (d, J = 7.7 Hz, 1 H), 4.27 
(d, J = 7.8 Hz, 1 H), 4.20-4.13 (m, 2 H), 4.00-3.97 (m, 2 H), 3.87 (dd, J = 7.7, 6.6 Hz, 1 H), 
3.78 (m, 1 H), 3.63 (m, 1 H), 3.54 (dd, J = 9.0, 7.8 Hz, 1 H), 3.51 (m, 1 H), 2.81-2.73 (m, 1 
H), 2.58-2.31 (m, 5 H), 1.79-1.24 (m, 29 H), 0.90 (t, J = 7.3 Hz, 3 H), 0.81 (s, 9 H), 0.37 (s, 3 
H), 0.24 (s, 3 H), 0.05 (s, 3 H), –0.04 (s, 3 H); 13C NMR (100 MHz, CDCl3): δ = 209.6, 171.4, 
166.8, 166.3, 164.4, 144.7, 138.4, 138.2, 133.8, 132.7, 128.6, 128.2, 127.8, 127.5, 126.8, 
126.6, 109.7, 101.5, 99.8, 82.0, 79.4, 76.5, 76.4, 75.6, 73.1, 71.7, 68.4, 68.3, 61.7, 42.3, 37.3, 
37.0, 33.7, 28.7, 28.3, 28.0, 27.8, 26.3, 25.7, 3.7, 18.4, 18.0, 16.8, 14.4, 14.3, 12.1, –24.0, 2
0.5, –1.6, –3.8, –4.9; IR (film): ν~  = 3069, 2932, 2858, 1733, 1652, 1588, 1248, 1155, 1074, 
839, 780, 730, 701; MS (EI): m/z (%): 83 (91), 157 (29), 265 (100), 349 (13), 767 (36), 991 
(9); HRMS (ESI): m/z: calcd for C57H84O14Si2Na [M+ + Na]: 1071.52919, found: 1071.53009. 
 
Compound 36: Prepared analogously from diene 35 (51 mg, 0.0484 mmol) as a colorless 
solid (37 mg). [ ]20Dα  = +3.5 (c = 0.52, CH2Cl2); 1H NMR (400 MHz, CD2Cl2): δ = 7.48-7.46 
(m, 2 H), 7.28-7.18 (m, 6 H), 6.98-6.96 (m, 2 H), 6.83 (m, 1 H), 6.32 (s, 1 H), 5.26 (t, J = 9.6 
Hz, 1 H), 5.17 (t, J = 9.6 Hz, 1 H), 5.03 (d, J = 8.0 Hz, 1 H), 4.26-4.22 (m, 2 H), 4.18-4.13 
(m, 2 H), 3.99 (dd, J = 2.0, 5.7 Hz, 1 H), 3.81 (dd, J = 6.6, 8.1 Hz, 1 H), 3.78 (m, 1 H), 3.69 
(m, 1 H), 3.56 (dd, J = 7.8, 8.9 Hz, 1 H), 3.51-3.49 (m, 1 H), 2.27-2.22 (m, 2 H), 1.78-1.27 
(m, 35 H), 0.91 (t, J = 7.2 Hz, 3 H), 0.82 (s, 9 H), 0.34 (s, 3 H), 0.27 (s, 3 H), 0.08 (s, 3 H), –
0.03 (s, 3 H); 13C NMR (125 MHz, CD2Cl2): δ = 173.2, 167.2, 166.5, 164.6, 145.3, 138.9, 
138.6, 134.3, 133.1, 128.9, 128.6, 128.2, 127.8, 127.1, 127.0, 110.0, 102.3, 100.1, 82.7, 80.2, 
76.9, 76.1, 73.6, 72.3, 68.8, 61.3, 38.0, 34.6, 30.1, 29.0, 28.6, 28.3, 28.0, 27.9, 26.4, 25.8, 
24.7, 24.4, 18.7, 18.3, 16.9, 14.6, 14.4, 12.2, –0.7, –1.3, –3.5, –4.8; IR (film): ν~  = 2929, 
2858, 1732, 1246, 1150, 1071, 1037, 837, 778, 729, 698. MS (EI): m/z (%): 83 (90), 135 (10), 
157 (32), 205 (11), 265 (100), 335 (10), 409 (7), 495 (7), 595 (6), 753 (43), 977 (11); HRMS 
(ESI): m/z: calcd for C57H86O13Si2Na [M+ + Na]: 1057.54992, found: 1057.55069. 
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Compound 46: Prepared analogously from diene 45 (74 mg, 0.0653 mmol) as a colorless 
syrup (60 mg, 83 %). [ ]20Dα  = +0.4 (c = 0.77, CH2Cl2); 1H NMR (400 MHz, CDCl3): δ = 7.46-
7.44 (m, 2 H), 7.29-7.19 (m, 6 H), 6.99-6.97 (m, 2 H), 6.81 (m, 1 H), 6.31 (s, 1 H), 5.28 (t, J = 
9.2 Hz, 1 H), 5.06-5.00 (m, 2 H), 4.94 (d, J = 7.7 Hz, 1 H), 4.25 (d, J = 7.8 Hz, 1 H), 4.13 (t, 
J = 6.0 Hz, 1 H), 4.03-4.02 (m, 1 H), 3.98 (dd, J = 5.8, 2.0 Hz, 1 H), 3.86 (dd, J = 7.8, 6.4 Hz, 
1 H), 3.78 (m, 1 H), 3.65 (dt, J = 10.0, 2.7 Hz, 1 H), 3.54-3.48 (m, 2 H), 2.87 (dt, J = 18.8, 6.8 
Hz, 1 H), 2.62 (dt, J = 18.8, 6.8 Hz, 1 H), 2.49 (m, 2 H), 2.14 (s, 3 H), 1.77-1.26 (m, 30 H), 
0.09 (t, J = 7.3 Hz, 3 H), 0.81 (s, 9 H), 0.37 (s, 3 H), 0.23 (s, 3 H), 0.05 (s, 3 H), –0.04 (s, 3 
H); 13C NMR (100 MHz, CDCl3): δ = 205.9, 170.9, 170.6, 166.8, 166.6, 164.4, 144.6, 138.3, 
138.0, 133.6, 132.5, 128.7, 128.2, 127.9, 127.6, 126.9, 126.6, 109.7, 101.3, 99.7, 81.9, 79.4, 
78.4, 77.2, 76.3, 75.4, 73.1, 71.6, 68.5, 68.3, 61.8, 37.3, 33.9, 33.8, 29.9, 28.5, 28.0, 27.8, 
6.3, 25.6, 24.2, 20.6  18.0, 16.8, 14.4, 14.3, 12.1, –0.4, –1.6, –3.8, –4.9; IR (film): , 18.3, ν~2  = 
C
 24.6, 18.7, 18.3, 16.9, 14.6, 14.4, 12.3, –0.2, –1.6, –3.4, –
3069, 2931, 2858, 1732, 1652, 1588, 1379, 1371, 1247, 1155, 1074, 839, 780, 731, 702; MS 
(EI): m/z (%): 83 (66), 157 (26), 265 (100), 567 (11), 825 (41), 1049 (9); HRMS (ESI): m/z: 
calcd for C59H86O16Si2Na [M+ + Na]: 1129.53466, found: 1129.53524. 
 
Compound 51: Prepared analogously from diene 50 (133 mg, 0.11 mmol) as a colorless solid 
(99.6 mg). [ ]20Dα  = –3.3 (c = 0.89, CH2Cl2); 1H NMR (400 MHz, CD2Cl2): δ = 7.49-7.47 (m, 2 
H), 7.30-7.19 (m, 8 H), 7.00-6.97 (m, 2 H), 6.90-6.85 (m, 3 H), 6.31 (s, 1 H), 5.25 (t, J = 9.5 
Hz, 1 H), 5.13 (t, J = 9.8 Hz, 1 H), 4.97 (d, J = 7.8 Hz, 1 H), 4.51 (d, J = 11.6 Hz, 1 H), 4.36 
(d, J = 11.6 Hz, 1 H), 4.26-4.22 (m, 2 H), 4.15 (t, J = 6.1 Hz, 1 H), 3.98 (dd, J = 5.8, 2.0 Hz, 1 
H), 3.80 (s, 3 H), 3.79-3.75 (m, 4 H), 3.68 (m, 1 H), 3.53 (dd, J = 9.0, 7.8 Hz, 1 H), 3.51-3.47 
(m, 1 H), 3.04 (ddd, J = 19.2, 8.9, 5.6 Hz, 1 H), 2.64 (dt, J = 19.2, 5.7 Hz, 1 H), 2.44 (ddd, J = 
16.6, 8.9, 5.5 Hz, 1 H), 2.17 (dt, J = 16.6, 5.7 Hz, 1 H), 1.77-1.25 (m, 29 H), 0.90 (t, J = 7.2 
Hz, 3 H), 0.82 (s, 9 H), 0.38 (s, 3 H), 0.23 (s, 3 H), 0.08 (s, 3 H), –0.01 (s, 3 H); 13C NMR 
(125 MHz, CD2 l2): δ = 211.6, 171.6, 167.1, 166.8, 164.7, 159.9, 145.3, 139.0, 138.8, 134.2, 
133.1, 130.4, 129.9, 129.0, 128.6, 128.2, 127.9, 127.2, 127.0, 114.2, 110.0, 102.3, 100.4, 84.5, 
82.7, 80.1, 77.3, 76.9, 76.0, 73.5, 72.3, 68.8, 68.7, 62.1, 62.1, 55.6, 37.9, 34.1, 33.4, 31.9, 
29.0, 28.6, 28.0, 26.4, 25.9, 24.8,
 30
4.7; IR (film): ν~  
.7, 
= 2933, 2859, 1732, 1652, 1612, 1587, 1513, 1248, 1155, 1074, 1038, 839, 
13
, 73.1, 71.6, 68.4, 68.3, 61.6, 42.2, 
6.9, 35.0, 33 32.0, 28.6, 7.9, 27.7, 26.2, 25.6, 24.7, 24.0, 23.6, 22.5, 17.9, 16.7, 
4.9; IR (film): 
818, 780, 730, 701; MS (EI): m/z (%): 83 (32), 121 (100), 157 (12), 211 (1), 265 (52), 323 (2), 
645 (2), 903 (5), 1127 (2); HRMS (ESI): m/z: calcd for C65H92O16Si2Na [M+ + Na]: 
1207.58162, found: 1207.58256. 
 
Compound 57: Prepared analogously from diene 56 (72 mg, 0.065 mmol) as a colorless solid 
(57 mg, 81 % over two steps). [ ]20Dα  = + 1.2 (c = 1, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 
7.47-7.45 (m, 2 H), 7.28-7.18 (m, 6 H), 6.97-6.95 (m, 2 H), 6.87-6.85 (m, 1 H), 6.31 (s, 1 H), 
5.28 (t, J = 9.3 Hz, 1 H), 5.08 (t, J = 9.8 Hz, 1 H), 4.93 (d, J = 7.7 Hz, 1 H), 4.26 (d, J = 7.8 
Hz, 1 H), 4.21-4.11 (m, 2 H), 4.00-3.97 (m, 2 H), 3.90-3.86 (m, 1 H), 3.80-3.77 (m, 1 H), 
3.65-3.62 (m, 1 H), 3.56-3.52 (m, 1 H), 3.52-3.47 (m, 1 H), 2.82-2.74 (m, 1 H), 2.58-2.33 (m, 
5 H), 1.79-1.78 (m, 6 H), 1.71-1.24 (m, 27 H), 0.89 (t, J = 7.3 Hz, 3 H), 0.82 (s, 9 H), 0.37 (s, 
3 H), 0.24 (s, 3 H), 0.06 (s, 3 H), −0.03 (s, 3 H); C NMR (100 MHz, CDCl3): δ = 209.5, 
171.3, 166.7, 166.3, 164.3, 144.6, 138.4, 138.1, 133.7, 132.6, 128.6, 128.2, 127.8, 127.5, 
126.8, 126.5, 109.6, 101.5, 99.7, 82.4, 79.4, 76.4, 76.3, 75.6
3 28.2, 2
ν~  14.4, 14.0, 12.1, −0.5, −1.6, −3.8, − = 2931, 2858, 1732, 1652, 1587, 1458, 
ted,  trif
1380, 1321, 1247, 1153, 1073, 1038, 838, 816, 779, 730, 700; HRMS (ESI): m/z: calcd for 
C59H88O14Si2Na [M+ + Na]: 1099.5599, found: 1099.5604. 
 
Completion of the total syntheses 
Ipomoeassin B (2). A solution of TASF (79 mg, 0.286 mmol) in MeCN (2.0 mL) was added 
to a solution of compound 32 (30 mg, 0.0286 mmol) in wet MeCN (1.5 mL). After stirring for 
4 h, the mixture was filtered through a pad of silica which was carefully rinsed with EtOAc, 
the combined filtrates were evapora  and the residue was treated with luoroacetic acid 
(16 μL, 215 mmol) in CH2Cl2 (2.0 mL). After stirring for 3 h, the solution was neutralized 
with Et3N, the solvent was evaporated, and the residue purified by flash chromatography 
(CH2Cl2/MeOH, 20/1) to afford Ipomoeassin B (2) as a colorless syrup which solidifies when 
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kept in the freezer (10 mg, 45 %). [ ]25Dα  = –48.0 (c = 0.36, EtOH); lit.8 [ ]25Dα  = –39 (c = 0.3, 
EtOH); For a compilation of the 1H and 13C NMR data of the synthetic samples and a 
comparison with the data of the l products, see Ta
formation; IR (film): 
natura bles 5 and 6 in the Supporting 
ν~  In = 3365, 3062, 2932, 1744, 
/z: c
1719, 1631, 1371, 1316, 1265, 1249, 
1157, 1138, 1073; MS (EI): m/z (%): 513 (11), 467 (14), 349 (10), 241 (13), 223 (42), 131 
(44), 111 (13), 83 (100), 55 (28); HRMS (ESI): m alcd for C40H56O14Na [M+ + Na]: 
783.35623, found: 783.35629. 
 
4-Deoxy-ipomoeassin B (38): Prepared analogously from compound 36 (15 mg, 0.0145 
mmol) as a colorless syrup (6.1 mg, 56 % overall). [ ]20Dα  = –33 (c = 0.29, EtOH); 1H NMR 
(400 MHz, C6D6): δ = 7.81 (d, J = 16.0 Hz, 1 H), 7.06-6.90 (m, 6 H), 6.38 (d, J = 16.0 Hz, 1 
H), 5.77 (t, J = 9.8 Hz, 1 H), 5.39 (br. m, 1 H), 4.69 (br. m, 1 H), 4.52-4.46 (m, 2 H), 4.38 (d, 
J = 7.6 Hz, 1 H), 4.20 (d, J = 11.9 Hz, 1 H), 3.91-3.75 (m, 3 H), 3.58 (m, 1 H), 3.45 (br. s, 1 
H), 3.37 (m, 1 H), 3.08 (br. q, J = 6.2 Hz, 1 H), 2.61-2.51 (m, 2 H), 2.39-2.33 (m, 1 H), 1.79-
1.56 (m, 30 H), 0.99 (t, J = 6.8 Hz, 3 H); 13C NMR (75 MHz, C6D6): δ = 173.2, 168.8, 165.4, 
146.2, 139.5, 134.4, 130.4, 128.9, 128.5, 128.0, 117.5, 106.5, 100.5, 84.0, 79.0, 76.8, 74.4, 
4.2, 73.0, 71.6, 70.2, 67.9, 61.5, 37.4, 34.5, 34.0, 29.3, 27.7, 27.6, 27.0, 25.2, 24.6, 18.7, 
769.3
e Tables 11 and 12 in e Supporting Information; IR (film): 
7
16.6, 14.4, 14.1, 12.0. MS (EI): m/z (%): 55 (24), 83 (100), 131 (42), 209 (13), 335 (9), 453 
(17), 499 (8), 583 (6), 629 (4); HRMS (ESI): m/z: calcd for C40H58O13Na [M+ + Na]: 
7696, found: 769.37677. 
 
Ipomoeassin E (5): Prepared analogously from compound 46 (30 mg, 0.027 mmol) as a 
colorless syrup which solidifies when kept in the freezer (14 mg, 63 % over both steps). 
[ ]25Dα  = –32 (c = 0.21, EtOH); lit.8 [ ]25Dα  = –24 (c = 0.2, EtOH); For a compilation of the 1H 
and 13C NMR data of the synthetic samples and a comparison with the data of the natural 
products, se  th ν~  = 3408, 2933, 
869, 1725, 1636, 1450, 1374, 1309, 1248, 1156, 1073, 768; MS (EI): m/z (%): 655 (5), 571 2
(7), 525 (7), 407 (9), 281 (40), 239 (11), 221 (19), 192 (11), 131 (58), 110 (10), 83 (100), 55 
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(20), 43 (19); HRMS (ESI): m/z: calcd for C42H58O16Na [M+ + Na]: 841.36172, found: 
841.36245. 
Compound 58: A solution of compound 57 (25.6 mg, 0.025 mmol) in MeCN (1.5 mL) was 
added to a solution of TASF (68 mg, 0.246 mmol) in MeCN (2 mL) and water (5 μL). After 
stirring overnight, the solvent was evaporated and the residue purified by flash 
chromatography (hexanes/EtOAc, 6:1) to give product 58 as a colorless syrup (8.8 mg, 43 %). 
[ ]20Dα  = –29 (c = 0.11, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 7.61 (d, J = 16.2 Hz, 1 H), 
7.48 – 7.50 (m, 2 H), 7.36 – 7.39 (m, 3 H), 6.84 – 6.90 (m, 1 H), 6.32 (d, J = 16.0 Hz, 1 H), 
5.23 – 5.32 (m, 2 H), 4.64 (d, J = 7.6 Hz, 1 H), 4.41 (dd, J = 2.8, 12.4 Hz, 1 H), 4.32 (d, J = 
8.1 Hz, 1 H), 4.20 (dd, J = 7.5, 5.7 Hz, 1 H), 4.11 (dd, J = 12.1, 2.3 Hz, 1 H), 4.01 (dd, J = 
5.4, 2.2 Hz, 1 H), 3.80 (dd, J = 6.6, 2.0 Hz, 1 H), 3.72 (dt, J = 9.3, 2.7 Hz, 1 H), 3.64 (t, J = 
7.9 Hz, 2 H), 3.59 (quint., J = 5.4 Hz, 1 H), 2.42 – 2.75 (m, 6 H), 1.75 – 1.78 (m, 3 H), 1.72 – 
1.74 (m, 3 H
 
), 1.61 – 1.68 (m, 3 H), 1.52 (s, 3 H), 1.39 – 1.51 (m, 4 H), 1.38 (d, J = 6.6 Hz, 3 
) 1.33 (s, 3 H), 1.21 – 1.32 (m, 12 H), 0.89 (t, J = 6.8 Hz, 3 H); 13C NMR (150 MHz, H
CDCl3): δ = 210.2, 171.7, 167.6, 165.4, 146.0, 138.6, 134.0, 130.5, 128.9, 128.3, 127.8, 
116.8, 110.3, 105.1, 100.0, 82.4, 79.8, 78.5, 76.5, 74.2, 73.9, 72.3, 68.5, 68.3, 65.9, 61.9, 42.0, 
37.4, 34.5, 33.2, 32.0, 29.3, 29.0, 28.5, 27.9, 26.2, 24.8, 24.6, 23.7, 22.7, 16.6, 15.3, 14.5, 
14.2, 12.1. 
 
Compound 59: A solution of compound 58 (4.3 mg, 0.0052 mmol) and trifluoroacetic acid 
(3.8 μL, 0.0511 mmol) in CH2Cl2 (1 mL) was stirred for 2 h. After neutralization with 
NaHCO3, all volatile materials were removed under reduced pressure and the resulting crude 
material (8.1 mg) was used in the next step. For analytical purposes, a small sample was 
purified by preparative HPLC (Shimadzu LC-8A/10A, MeOH/H2O, 85:15, 10 mL/min, 6.3 
MPa), which analyzed as follows: 1H NMR (400 MHz, C6D6): δ = 7.82 (d, J = 16.0 Hz, 1 H), 
7.07-6.89 (m, 6 H), 6.40 (d, J = 16.0 Hz, 1 H), 5.73 (t, J = 9.7 Hz, 1 H), 5.43 (t, J = 9.4 Hz, 1 
H), 4.66-4.63 (m, 1 H), 4.56-4.54 (m, 1 H), 4.39 (d, J = 7.6 Hz, 1 H), 4.19 (d, J = 12.4 Hz, 1 
H), 3.96-3.92 (m, 1 H), 3.88-3.84 (m, 1 H), 3.73 (m, 1 H ), 3.64-3.61 (m, 1 H), 3.49 (s, 1 H), 
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3.43-3.40 (m, 1 H), 3.13-3.08 (m, 1 H), 2.62 (ddd, J = 3.4, 7.7, 16.1 Hz, 1 H), 2.56-2.54 (m, 1 
H), 2.43-2.35 (m, 1 H), 2.18-2.11 (m, 1 H), 2.08 (t, J = 6.2 Hz, 2 H), 1.72 (s, 3 H), 1.67-1.27 
(m, 24 H), 0.93 (t, J = 6.9 Hz, 3 H); 13C NMR (100 MHz, C6D6): δ = 208.3, 171.5, 168.4, 
65.6, 146.1, 139.3, 134.4, 130.3, 128.8, 128.5, 127.9, 117.6, 106.3, 100.6, 83.6, 79.3, 76.6, 
74.5, 74.1, 73.1, 71.7, 70.2, 67.8, 
1
1
61.4, 41.5, 37.4, 35.2, 34.4, 32.3, 29.5, 29.4, 28.6, 25.4, 
2.0; IR (film): 25.3, 23.7, 23.1, 16.6, 14.3, 14.1, ν~  = 3374, 2929, 2856, 1745, 1718, 1632, 
, 1072, 905, 864, 767, 729, 685; HRMS (ESI): m/z: calcd 
82, found: 811.3875. 
Compound 60: Prepared analogously upon stirring of 58 
(62 mg, 0.075 mmol) and trifluoroacetic acid (926 μL, 
12.0 mmol) in CH2Cl2 (9 mL) for 2 h. The mixture was 
neutralized with Et3N before all volatile materials were 
evaporated and the residue was purified by flash 
chromatography (CH2Cl2/MeOH, 60:1) to give product 
60 as a colorless syrup (32 mg, 54 %). 1H NMR (600 
MHz, C6D6): δ = 7.84 (d, J = 16.0 Hz, 1 H, H-48), 7.11 (m, 1 H, H-43); 7.01 (m, 1 H, H-50), 
6.94 (m, 1 H, H-52), 6.91 (m, 1 H, H-51), 6.49 (d, J = 16.0 Hz, 1 H, H-47), 5.79 (t, J = 9.5 
Hz, 1 H, H-3), 5.59 (dd, J = 9.6, 8.1 Hz, 1 H, H-2), 5.44 (d, J = 7.9 Hz, 1 H, H-1), 4.96 (d, J = 
12.2 Hz, 1 H, H-6a), 4.26 (d, J = 7.6 Hz, 1 H, H-31), 4.21 (d, J = 12.6 Hz, 1 H, H-6b), 4.06 (t, 
J = 9.6 Hz, 1H, H-4), 3.97 (dd, J = 7.6, 9.0 Hz, 1H, H-32), 3.66 (m, 1H, H-17), 3.54-3.59 (m, 
2 H, H-5, H-33), 3.42 (br. s, 1 H, H-34), 3.02 (m, 1 H, H-35), 2.45 (m, 1 H, H-8a), 2.36 (m, 1 
H, H-9a), 2.24 (m, 1 H, H-8b), 2.16 (m, 1 H, H-11a), 2.09 (m, 2 H, H-9b, H-11b), 1.86 (s, 3 
H, H-45), 1.26-1.78 (m, 23 H), 1.37 (d, J = 6.5 Hz, 3 H, H-44), 1.20 (d, J = 6.5 Hz, 3 H, H-
36), 0.91 (t, J = 6.7 Hz, 3 H, H-22); 13C NMR (150 MHz, C6D6): δ = 209.6 (C-10), 173.3 (C-
7), 167.3 (C-41), 166.9 (C-46), 145.9 (
O
1449, 1380, 1372, 1315, 1250, 115




C-48), 138.5 (C-43), 134.7 (C-49), 130.1 (C-52), 128.9 
-51), 128.8 (C-42), 127.7 (C-50), 118.2 (C-47), 101.6 (C-31), 101.5 (C-1), 80.1 (C-17), 
(C-5), 74.9 (C-33), 73.1 (C-2), 72.2 (C-34), 70.2 (C-35), 68.6 
(C-4), 63.1 (C-6), 42.1 (C-11), 37.1 (C-9), 35.4 (C-16), 34.3 (C-18), 29.1 (C-8), 28.7 (C-13), 
(C













































25.4 (C-15), 24.6 (C-19), 24.1 (C-12), 23.13 (C-20), 23.08 (C-14), 20.6 (C-21), 16.5 (C-36), 
14.4 (C-22), 14.2 (C-44), 12.4 (C-45). 
 
Orthoester rearrangements 
Ipomoeassin A (1): Camphersulfonic acid (1.0 mg) was added to a solution of ipomoeassin B 
(2) (2.4 mg, 0.00315 mmol) in triethyl orthoacetate (0.10 mL) and the mixture was stirred for 
1 h before aq. acetic acid (80 % w/w, 0.10 mL) was introduced and stirring continued for 3 h. 
Evaporation of the solvent and flash column chromatography of the crude material 
(CH2Cl2/MeOH, 30/1) gave ipomoeassin A as a colorless oil (2.4 mg, 95 %). For a 
compilation of the 1H and 13C NMR data of the synthetic samples and a comparison with the 
ata of the natural products, see Tables 3 and 4 in the Supporting Information.  = –22 [ ]25Dαd
(c = 0.1, EtOH); lit.8 [ ]25Dα  = –36 (c = 0.2, EtOH); MS (EI): m/z (%): 55 (22), 83 (99), 131 
(100), 192 (13), 223 (29), 349 (14), 597 (15); HRMS (ESI): m/z: calcd for C42H58O15Na [M+ + 
Na]: 825.36680, found: 825.36615. 
 
Ipomoeassin C (3): Prepared analogously starting with compound 51 (29.1 mg, 0.0368 
mmol) as a colorless oil (5.9 mg, 30 % overall). For a compilation of the 1H and 13C NMR 
ata of the synthetic samples and a comparison with the data of the natural products, see d
Tables 7 and 8 in the Supporting Information. [ ]25Dα  = –20 (c = 0.3, EtOH); lit.8 [ ]25Dα  = –29 
(c = 0.4, EtOH); MS (EI): m/z (rel. intensity): 55 (18) 131 (100), 149 (6), 245 (6), 375 (20) 
417 (7); HRMS (ESI): m/z: calcd for C42H58O16Na [M+ + Na]: 841.36171, found: 841.36128. 
 
Ipomoeassin D (4): Prepared analogously from ipomoeassin E (5) (13 mg, 0.0159 mmol) as a 
colorless oil (12.3 mg, 90 %). For a compilation of the 1H and 13C NMR data of the synthetic 
Supp 0 (c
samples and a comparison with the data of the natural products, see Tables 9 and 10 in the 
orting Information. [ ]25Dα  = –3  = 0.2, EtOH); lit.8 [ ]25Dα  = –35 (c = 0.2, EtOH); MS 
EI): m/z (%): 83 (72), 131 (100)192 (12), 281 (26), 407 (11), 655 (6), 701 (4); HRMS (ESI): 
m/z: calcd for C44H60O17Na [M+ + Na]. 883.37227, found: 883.37305. 
(
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Ipomoeassin F (6): Prepared analogously as a colorless oil (4.8 mg, 96 %, overall from 58). 
[ ]20Dα  = −33 (c = 0.16, EtOH); lit.9 [ ]22Dα  = −54 (c = 0.16, EtOH); 1H NMR (400 MHz, C6D6): 
δ = 7.81 (d, J = 16.0 Hz, 1 H), 7.06-6.90 (m, 4 H), 6.38 (d, J = 16.0 Hz, 1 H), 5.69 (t, J = 9.7 
Hz, 1 H), 5.44 (t, J = 9.5 Hz, 1 H), 5.18-5.17 (m, 1 H), 4.70-4.66 (m, 1 H), 4.58 (d, J = 7.7 
Hz, 1 H), 4.41 (d, J = 7.6 Hz, 1 H), 4.14 (d, J = 12.4 Hz, 1 H), 3.97-3.87 (m, 2 H), 3.78-3.69 
(m, 2 H), 3.36 (d, J = 9.7 Hz, 1 H), 3.18-3.12 (m, 1 H), 2.66 (ddd, J = 16.1, 7.7, 3.4 Hz, 1 H), 
2.56-2.48 (m, 1 H), 2.44-2.36 (m, 1 H), 2.20-2.12 (m, 1 H), 2.08 (t, J = 6.0 Hz, 2 H), 1.86 (s, 
3 H), 1.72 (s, 3 H), 1.67-1.17 (m, 22 H), 1.26 (d, J = 17.0 Hz, 3 H), 1.12 (d, J = 6.4 Hz, 3 H), 
0.92 (t, J = 6.9 Hz, 3 H); 1H NMR (600 MHz, CDCl3): δ = 7.61 (d, J = 16.1 Hz, 1 H), 7.48 
(m, 2 H), 7.37 (m, 1 H), 7.36 (m, 2 H), 6.87 (qq, J = 7.0, 1.4 Hz, 1 H), 6.32 (d, J = 16.0 Hz, 1 
H), 5.29 (dd, J = 9.8, 9.8 Hz, 1 H), 5.12 (dd, J = 3.7, 0.9 Hz, 1 H), 5.11 (dd, J = 9.5, 9.5 Hz, 1 
H), 4.59 (d, J = 7.8 Hz, 1 H), 4.44 (dd, J = 12.4, 3.5 Hz, 1 H), 4.38 (d, J = 7.7 Hz, 1 H), 4.12 
(dd, J = 12.4, 2.4 Hz, 1 H), 3.89 (dd, J = 9.6, 3.7 Hz, 1 H), 3.72 (ddd, J = 9.8, 3.5, 2.4 Hz, 1 
H), 3.63 – 3.68 (m, 3 H), 3.61 (t, J = 5.7 Hz, 1 H), 2.77 (ddd, J = 17.6, 9.1, 4.1 Hz, 1 H), 2.71 
(ddd, J = 17.2, 7.3, 3.8 Hz, 1 H), 2.63 (ddd, J = 16.6, 7.3, 4.1 Hz, 1 H), 2.55 (ddd, J = 16.3, 
9.0, 3.9 Hz, 1 H), 2.47 (ddd, J = 16.0, 8.1, 4.6 Hz, 1 H), 2.41 (ddd, J = 16.0, 9.0, 5.6 Hz, 1 H), 
2.16 (s, 3 H), 1.70 – 1.74 (m, 6 H), 1.63 (m, 4 H), 1.49 (m, 4 H), 1.26 (m, 13 H), 1.16 (d, J = 
6.4 Hz, 3 H), 0.86 ( t, J = 7.2 Hz, 3 H); 13C NMR (150 MHz, CDCl3): δ = 210.1, 171.9, 171.7, 
168.9, 165.4, 146.2, 139.9, 133.9, 130.7, 128.9, 128.3, 127.5, 116.6, 105.7, 100.1, 82.8, 79.7, 
75.9, 73.9, 72.7, 72.6, 72.5, 68.8, 67.4, 61.7, 41.9, 37.6, 34.3, 33.0, 31.9, 29.1, 29.0, 28.3, 
24.6, 24.5, 23.5, 22.7, 21.0, 16.4, 14.7, 14.1, 12.0; 13C NMR (100 MHz, C6D6): δ = 208.4, 
171.7, 170.9, 168.5, 165.6, 146.3, 139.2, 134.6, 130.7, 128.8, 128.5, 127.9, 117.7, 106.6, 
 84.0, 79.4, 76.5, 74.8, 73.0  72.8, 69.0, 67.8, 61.5, 41.6, 37.4, 35.4, 34.3, 32.3, 100.8, , 72.8,
29.7, 29.4, 28.7, 25.5, 25.2, 23.7, 23.1, 20.5, 16.6, 14.3, 14.1, 12.0; IR (film): ν~  = 3418, 
2930, 2857, 1721, 1636, 1450, 1379, 1310, 1248, 1155, 1073; HRMS (ESI): m/z: calcd for 
C44H62O15Na [M+ + Na]: 853.3988, found: 853.3981. 
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X-ray crystal structure analysis of compound 17a: C30 H44 O11, Mr = 580.65 g·mol-1, 
colorless block, crystal size 0.26 x 0.08 x 0.02 mm, monoclinic, space group P21, a = 
17.1161(5) Å, b = 5.5117(2) Å, c = 8.3107(3) Å, β = 117.278(1)°, V = 1476.85(8) Å3, T = 
92 independent reflections, 7390 reflections with I > 
σ(I), Structure solved by direct methods and refined by full-matrix least-squares against F2 to 
[I > 2σ(I)], wR2 = 0.103, absolute structure parameter = −0.2(6), 378 parameters, 
s the internal methanol 
ontrol. After 5 d incubation, 20 μL of 5 mg mL−1 MTT (thiazolyl blue tetrazolium bromide) 
100 K, Z = 2, Dcalc = 1.306 g·cm3, λ = 0.71073 Å, μ(Mo-Kα) = 0.099 mm-1, Multi-Scan 
absorption correction (Tmin = 0.76, Tmax = 0.86), Nonius KappaCCD diffractometer, 3.43 < θ < 
33.21, 39545 measured reflections, 112
2
R1 = 0.056 
H atoms riding, S = 1.009, residual electron density +0.3 / −0.2 e Å-3. 
CCDC-732392 contains the supplementary crystallographic data of this paper. These data can 




Cell culture: The L-929 cell line and the HeLa cells (ATCC Nr. CCL-2) were obtained from 
the German Collection of Microorganisms and Cell Cultures (DSMZ) and were cultured 
under conditions recommended by the depositor. Cell culture reagents were purchased from 
Sigma-Aldrich and plastic ware was obtained from Sarstedt AG & Co. 
 
Cytotoxicity assays: L-929: Cells were seeded at 6·103 cells per well of 96-well plates in 180 
μL complete medium and directly treated with varying concentrations of ipomoeassins diluted 
in methanol. Each ipomoeassin was tested in duplicate as well a
c
in PBS was added per well and it was further incubated for 2 h at 37 °C. The medium was 
then discarded and cells were washed with 100 μL PBS before adding 100 μL 2-propanol/10 
M HCl (250:1) in order to dissolve formazan granules. The absorbance at 570 nm was 
measured using a microplate reader (EL808, Bio-Tek Instruments Inc.), and cell viability was 
expressed as percentage relative to the respective methanol control.  
 
 37
HeLa: Cells were seeded at 5·103 cells per well on 96-well plates in 100 μL complete 
medium. Cells were incubated for 18-20 h at 37 °C / 5 % CO2 before the medium was 
exchanged for fresh medium containing the appropriate concentration of the compound to be 
sted. Compound stock solutions were prepared in DMSO at 10 mM. After incubation for 3 d 
 cold (−20 °C) 80 % ethanol. After fixation, ethanol was removed 
ompletely and the cell pellet was resuspended in a PBS solution containing 5 μg mL−1 
propidium iodide and 0.1 mg mL−1 RNase A. The suspension was incubated for 30 min at 
37 °C and samples were analyzed by a flowcytometric system (EasyCyte Plus, Guava 
Technologies). In total, 5000 viable cells were acquired per sample and cell cycle histograms 
were generated after exclusion of small cell debris using a Watson algorithm of FlowJo 7.2.5 
software (TreeStar Inc.). 
 
te
at 37 °C / 5 % CO2, 10 μL of a WST-1 ready-to-use solution (Roche) was added and the plate 
was kept at 37 °C for at least 30 min. Absorption was measured at 450 nm using an automatic 
plate reader (Tecan). Each measurement was repeated independently four times and cell 
viability was expressed as percentage of the mean value relative to the positive control; WST-
1 = (4-[3-(4-Iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate). 
 
Cell cycle analysis: 105 cells were harvested by centrifugation, washed with ice-cooled PBS, 
and fixed overnight with
c
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Table 3. Comparison of the published 1H NMR data 
(C6D6) of Ipomoeassin A (1) (500 MHz) with those 
of the synthetic sample (600 MHz). Numbering 















































Position Ipomoeassin A (J in Hz) Synthetic Sample (J in Hz)  
2 2.40 ddd (17.4, 9.4, 3.4) 
2.14 ddd (17.4, 7.7, 3.5) 
2.38 ddd (17.4, 9.8, 3.4) 
2.14 ddd (17.4, 7.5, 3.4) 
3 2.65 ddd (16.1, 7.7, 3.4) 
2.52 ddd (16.1, 9.4, 3.5) 
2.64 ddd (16.3, 7.5, 3.4) 
2.50 ddd (16.3, 9.8, 3.4) 
5 2.07 t (6.0) 2.06 t (6.0) 
11 3.72 m 3.72 m 
14 0.95 t (7.1) 0.95 t (6.9) 
1’ 4.40 d (7.7) 4.38 d (7.7) 
2’ 3.96 dd (9.5, 3.7) 3.86 app. t (9.2) 
3’ 3.72 dd (9.5, 3.7) 3.68 dd (9.6, 3.6) 
4’ 5.15 dd (3.7, 0.5) 5.11 brd (3.5) 
5’ 3.10 qd (6.4, 0.5) 3.09 brq (6.4) 
6’ 1.10 d (6.4) 1.09 d (6.4) 
1” 4.52 d (7.9) 4.48 d (8.0) 
2” 3.91 dd (9.7, 7.9) 3.92 dd (9.6, 7.8) 
3” 5.39 t (9.7) 5.31 t (9.4) 
4” 5.69 t (9.7) 5.67 t (9.8) 
5” 3.24 ddd (9.7, 3.2, 1.6) 3.23 brd (10.3) 
6” 4.66 dd (12.6, 3.2) 
4.11 dd (12.6, 1.6) 
4.63 dd (12.6, 3.1) 
4.11 brd (12.6) 
31 6.39 d (15.9) 6.38 d (16.0) 
32 7.81 d (15.9) 7.81 d (16.0) 
34 6.89-7.07 6.90-7.05 
35 6.89-7.07 6.90-7.05 
36 6.89-7.07 6.90-7.05 
42 6.95 m 6.96 m 
43 1.23 d (7.1) 1.25 d (7.0) 
44 1.68 brs 1.69 brs 
51 1.82 s 1.82 s 
 
[a] The protons H-6 to H-10, H-12 and H-13 appear between 1.96-1.36 ppm as a multiplet. 
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Table 4. Comparison of the 13C NMR data (C6D6) of Ipomoeassin A (1) (125 MHz) with 
those of the synthetic sample (150 MHz). 
 
 
Position Ipomoeassin A Synthetic sample 
1 171.5 171.5 
2 37.3 37.4 
3 29.7 29.6 
4 208.4 208.2 
5 41.6 41.6 
6 23.8 23.7 
7 28.7 28.7 
8 29.4 29.4 
9 25.5 25.5 
10 34.3 34.3 
11 79.0 78.9 
12 37.6 37.6 
13 18.7 18.7 
14 14.4 14.4 
1’ 100.8 100.7 
2’ 84.0 84.0 
3’ 72.7 72.8 
4’ 72.9 73.0 
5’ 69.0 69.0 
6’ 14.1 14.1 
1” 106.6 106.5 
2” 74.8 74.8 
3” 76.4 76.7 
4” 67.8 67.7 
5” 73.0 73.0 
6” 61.5 61.4 
30 165.6 165.6 
31 117.6 117.6 
32 146.1 146.1 
33 134.5 134.4 
34 128.5 128.5 
35 128.9 128.9 
36 130.4 130.4 
40 168.5 168.7 
41 128.0 128.0 
42 139.2 139.4 
43 16.6 16.5 
44 12.1 12.0 
50 171.0 170.8 












































Table 5. Comparison of the published 1H NMR data 
(C6D6) of Ipomoeassin B (2) (500 MHz) with those 
of the synthetic sample (300 MHz). Numbering 






Position Ipomoeassin B (J in Hz) Synthetic sample (J in Hz)  
2 2.38 ddd (17.4, 9.4, 3.4) 
2.13 ddd (17.4, 7.7, 3.5) 
2.37 ddd (17.1, 9.3, 3.5) 
2.15 ddd (17.1, 7.6, 3.3) 
3 2.62 ddd (16.1, 7.7, 3.4) 
2.50 ddd (16.1, 9.4, 3.5) 
2.63 ddd (16.1, 7.7, 3.3) 
2.49 ddd (16.1, 9.2, 3.4) 
5 2.07 t (6.2) 2.08 t (6.2) 
11 3.71 m 3.73 m 
14 0.96 t (7.1) 0.97 t (7.0) 
1’ 4.38 d (7.6) 4.39 d (7.6) 
2’ 3.88 dd (9.5, 7.6) 3.88 dd (9.8, 7.5) 
3’ 3.65 dd (9.5, 3.3) 3.65 dd (9.6, 3.3) 
4’ 3.53 brs 3.53 br s 
5’ 3.11 brq (6.4) 3.11 br q (6.3) 
6’ 1.29 d (6.4) 1.29 d (6.4) 
1” 4.59 d (7.8) 4.61 d (7.8) 
2” 3.95 dd (9.7, 7.8) 3.95 dd (9.6, 8.0) 
3” 5.50 t (9.7) 5.51 t (9.6) 
4” 5.72 t (9.7) 5.73 t (9.6) 
5” 3.44 brd (9.7) 3.46 brm 
6” 4.66 dd (12.6, 2.1) 
4.16 brd (12.6) 
4.64 m 
4.18 br d (12.4) 
31 6.40 d (16.1) 6.41 d (16.0) 
32 7.81 d (16.1) 7.82 d (16.0) 
34 6.88-7.07 6.88-7.08 
35 6.88-7.07 6.88-7.08 
36 6.88-7.07 6.88-7.08 
42 6.95 m 6.94 m 
43 1.27 d (7.1) 1.29 d (7.1) 
44 1.72 brs 1.73 brs 
 




Table 6. Comparison of the published 13C NMR data (C6D6) of Ipomoeassin B (2) (100 MHz) 
with those of the synthetic samples (150 MHz). 
 
Position Ipomoeassin B Synthetic Sample 
1 171.5 171.6 
2 37.4 37.4 
3 29.5 29.6 
4 208.3 208.5 
5 41.5 41.6 
6 23.6 23.7 
7 28.6 28.7 
8 29.3 29.4 
9 25.4 25.5 
10 34.3 34.4 
11 78.8 78.9 
12 37.4 37.4 
13 18.8 18.8 
14 14.3 14.4 
1’ 100.6 100.6 
2’ 83.7 83.7 
3’ 74.2 74.2 
4’ 71.6 71.7 
5’ 70.2 70.2 
6’ 14.0 14.1 
1” 106.4 106.5 
2” 74.6 74.6 
3” 76.3 76.4 
4” 67.8 67.9 
5” 73.0 73.1 
6” 61.4 61.5 
30 165.5 165.6 
31 117.6 117.7 
32 146.0 146.1 
33 134.4 134.5 
34 128.4 128.5 
35 128.8 128.9 
36 130.3 130.4 
40 168.5 168.6 
41 128.0 127.9 
42 139.1 139.2 
43 16.6 16.6 














































HO Table 7. Comparison of the published 1H NMR data 
(C6D6) of Ipomoeassin C (3) (500 MHz) with those of 
the synthetic sample (400 MHz). Numbering scheme as 
shown in the insert.[a] 
 
 
Position Ipomoeassin C (J in Hz) Synthetic sample (J in Hz)  
2 2.65 ddd (17.9, 9.1, 4.2) 
1.80 ddd (17.9, 7.8, 4.4) 
2.67 ddd (18.0, 9.2, 4.4) 
1.77 m 
3 3.01 ddd (16.4, 9.1, 4.4) 
2.21 ddd (16.4, 7.8, 4.4) 
3.01 ddd (16.4, 9.2, 4.4) 
2.24 ddt (16.4, 7.8, 4.4) 
5 3.96 m 3.96 m 
11 3.66 m 3.66 m 
14 0.96 t (6.9) 0.97 t (6.8) 
1’ 4.32 d (7.6) 4.33 d (7.6) 
2’ 3.90 dd (9.7, 7.6) 3.89 appt (9.6) 
3’ 3.66 dd (9.7, 3.4) 3.66 m 
4’ 5.12 brd (3.4) 5.11 brm 
5’ 3.11 brq (6.4) 3.13 brq (6.4) 
6’ 1.09 d (6.4) 1.10 d (6.4) 
1” 4.54 d (7.8) 4.53 brd (7.4) 
2” 3.83 dd (9.7, 7.8) 3.83 appt (9.2) 
3” 5.41 t (9.7) 5.39 brt (9.6) 
4” 5.72 t (9.7) 5.71 t (9.6) 
5” 3.26 brd (9.7) 3.27 m 
6” 4.37 dd (12.4, 1.6) 
4.26 dd (12.4, 0.9) 
4.37 brd (12.4) 
4.25 brd (12.4) 
31 6.38 d (16.0) 6.38 d (16.0) 
32 7.81 d (16.0) 7.81 d (16.0) 
34 6.88-7.03 6.91-7.07 
35 6.88-7.03 6.91-7.07 
36 6.88-7.03 6.91-7.07 
42 6.95 m 6.94 m 
43 1.27 d (7.1) 1.29 d (7.0) 
44 1.71 brs 1.72 brs 
51 1.84 s 1.84 s 
 
[a] The protons H 6-10, H-12 and H-13 appear between 1.80-1.30 ppm as a multiplet. 
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Table 8. Comparison of the 13C NMR data (C6D6) of Ipomoeassin C (3) (125 MHz) with 
those of the synthetic sample (75 MHz). 
 
 
Position Ipomoeassin C Synthetic sample 
1 171.6 171.6 
2 33.0 33.0 
3 28.3 28.3 
4 210.7 210.6 
5 76.3 76.4 
6 32.7 32.8 
7 22.7 22.7 
8 29.9 29.9 
9 25.1 25.1 
10 34.1 34.2 
11 78.8 78.9 
12 37.6 37.7 
13 18.8 18.8 
14 14.4 14.4 
1’ 100.7 100.8 
2’ 83.7 83.8 
3’ 72.7 72.8 
4’ 72.6 72.7 
5’ 68.9 69.0 
6’ 14.1 14.1 
1” 106.4 106.4 
2” 74.7 74.8 
3” 76.4 76.4 
4” 67.9 67.9 
5” 72.8 72.8 
6” 61.6 61.6 
30 165.4 165.4 
31 117.5 117.6 
32 146.2 146.2 
33 134.4 134.5 
34 128.5 128.5 
35 128.9 128.9 
36 130.4 130.4 
40 168.5 168.6 
41 128.0 128.0 
42 139.3 139.3 
43 16.5 16.5 
44 12.1 12.0 
50 171.0 170.9 





Table 9. Comparison of the published 1H NMR data 
(C6D6) of Ipomoeassin D (4) (500 MHz) with those of 
the synthetic sample (400 MHz). Numbering scheme as 



















































Position Ipomoeassin D (J in Hz) Synthetic Sample (J in Hz)  
2 2.57 ddd (18.1, 9.2, 2.8) 
2.38 ddd (18.1, 7.8, 3.4,) 
2.59 ddd (18.0, 9.3, 2.9) 
2.40 m 
3 2.83 ddd (16.3, 9.2, 3.4) 
2.43 ddd (16.3, 7.8, 2.8) 
2.84 ddd (16.5, 9.2, 3.6) 
2.42 brm 
5 5.05 dd (6.2, 3.9) 5.07 dd (6.3, 3.8) 
11 3.70 m 3.71 m 
14 0.95 t (7.1) 0.96 t (7.0) 
1’ 4.29 d (7.6) 4.31 d (7.9) 
2’ 3.88 dd (9.5, 7.6) 3.88 dd (9.6, 7.8) 
3’ 3.62 dd (9.5, 3.7) 3.64 brm 
4’ 5.09 brd (3.7) 5.10 brs 
5’ 3.06 brq (6.4) 3.09 brq (6.2) 
6’ 1.08 d (6.4) 1.09 d (6.4) 
1” 4.51 d (7.8) 4.50 brm 
2” 3.79 dd (9.7, 7.8) 3.80 brm 
3” 5.39 t (9.7) 5.39 brm 
4” 5.69 t (9.7) 5.69 t (9.8) 
5” 3.29 brd (9.7) 3.29 brm 
6” 4.51 brd (11.5) 
4.19 brd (11.5) 
4.50 br d (11.7) 
4.20 brd (11.7) 
21 1.70 s 1.72 s 
31 6.37 d (15.8) 6.38 d (16.0) 
32 7.81 d (15.8) 7.81 d (16.0) 
34 6.88-7.03 6.91-7.08 
35 6.88-7.03 6.91-7.08 
36 6.88-7.03 6.91-7.08 
42 6.95 m 6.96 m 
43 1.26 d (7.1) 1.28 brm 
44 1.70 brs 1.72 s 
51 1.82 s 1.82 s 
 
[a] The protons H-6 to H-10, H-12 and H-13 appear between 1.97-1.33 ppm as a multiplet. 
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Table 10. Comparison of the 13C NMR data (C6D6) of Ipomoeassin D (4) (125 MHz) with 
those of the synthetic sample (75 MHz). 
 
 
Position Ipomoeassin D Synthetic sample 
1 171.3 171.3 
2 34.0 34.1 
3 28.3 28.3 
4 205.7 205.7 
5 78.4 78.5 
6 30.3 30.4 
7 24.0 24.0 
8 30.6 30.6 
9 25.2 25.2 
10 34.0 34.1 
11 78.5 78.5 
12 37.7 37.7 
13 18.9 18.9 
14 14.4 14.4 
1’ 100.6 100.7 
2’ 83.9 83.9 
3’ 72.8 72.9 
4’ 72.7 72.7 
5’ 68.9 68.9 
6’ 14.1 14.1 
1” 106.6 106.6 
2” 75.0 75.0 
3” 76.6 76.4 
4” 67.6 67.8 
5” 72.9 72.9 
6” 61.2 61.3 
50 170.9 171.0 
51 20.4 20.5 
20 169.8 169.8 
21 20.3 20.3 
40 168.8 168.6 
41 128.0 128.0 
42 139.4 139.2 
43 16.5 16.5 
44 12.0 12.1 
30 165.5 165.5 
31 117.6 117.6 
32 146.2 146.2 
33 134.4 134.5 
34 128.4 128.3 
35 128.8 128.9 















































Table 11. Comparison of the 1H NMR data (C6D6) 
reported for Ipomoeassin E (5) (500 MHz) with those 
of the synthetic material (400 MHz). Numbering 




Position Ipomoeassin E (J in Hz) Synthetic sample (J in Hz) 
2 2.55 ddd (18.1, 9.2, 2.8) 
2.34 ddd (18.1, 7.8, 3.4) 
2.59 ddd (18.0, 9.2, 3.1) 
2.46-2.36 m 
3 2.81 ddd (16.3, 9.2, 3.4) 
2.39 ddd (16.3, 7.8, 2.8) 
2.82 ddd (16.5, 9.2, 3.5) 
2.46-2.36 m 
5 5.04 dd (6.2, 3.9) 5.07 dd (6.1, 3.9) 
11 3.71 m 3.74 brm 
14 0.97 t (6.9) 0.99 t (7.0) 
1’ 4.28 d (7.6) 4.32 d (7.6) 
2’ 3.80 dd (9.5, 7.6) 3.82 appt (9.4) 
3’ 3.55 dd (9.5, 3.7) 3.59 dd (9.3, 3.2) 
4’ 3.44 brs 3.48 brs 
5’ 3.02 brq (6.4) 3.09 brq (6.4) 
6’ 1.25 d (6.4) 1.28 d (6.6) 
1” 4.50 d (7.8) 4.55 d (8.0) 
2” 3.81 dd (9.7, 7.8) 3.84 appt (9.5) 
3” 5.38 t (9.7) 5.43 t (9.5) 
4” 5.70 t (9.7) 5.71 t (9.7) 
5” 3.36 brd (9.7) 3.43 brd (9.8) 
6” 4.51 dd (11.0, 2.0) 
4.20 brd (11.0) 
4.52 dd (11.4, 2.2) 
4.24 brd (11.5) 
21 1.67 brs 1.73 brs 
31 6.40 d (16.1) 6.41 d (16.0) 
32 7.81 d (16.1) 7.82 d (16.0) 
34 6.88-7.03 6.91-7.09 
35 6.88-7.03 6.91-7.09 
36 6.88-7.03 6.91-7.09 
42 6.95 m 6.95 m 
43 1.25 d (7.1) 1.30 d (7.3) 
44 1.67 brs 1.73 brs 
[a] The chemical shifts depend on the concentration of the sample and the dryness of the C6D6 used; the data 
compiled in this Table were recorded using 3 mg of compound 2 in 0.6 mL of freshly distilled (CaH2) C6D6. b 
The protons at positions H-6 to H-10, H-12 and H-13 appear between 1.96-1.36 ppm as a multiplet. 
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Table 12. Comparison of the 13C NMR data (C6D6) reported for Ipomoeassin E (5) (125 
MHz) with those of the synthetic sample (75 MHz). 
 
Position Ipomoeassin E Synthetic sample 
1 171.4 171.4 
2 34.0 34.1 
3 28.3 28.3 
4 205.8 205.7 
5 78.2 78.2 
6 30.3 30.3 
7 24.0 24.0 
8 30.5 30.5 
9 25.2 25.2 
10 34.0 34.1 
11 78.5 78.5 
12 37.7 37.7 
13 18.9 19.0 
14 14.4 14.4 
1’ 100.5 100.4 
2’ 84.2 84.3 
3’ 74.0 74.0 
4’ 71.6 71.6 
5’ 70.0 70.0 
6’ 14.1 14.1 
1” 106.7 106.7 
2” 74.9 74.9 
3” 76.6 76.7 
4” 67.7 67.7 
5” 72.9 73.0 
6” 61.2 61.3 
20 169.8 169.8 
21 20.3 20.3 
30 165.5 165.5 
31 117.5 117.6 
32 146.2 146.2 
33 134.4 134.5 
34 128.3 128.2 
35 128.5 128.3 
36 130.4 130.4 
40 168.9 168.9 
41 128.0 128.0 
42 139.6 139.5 
43 16.6 16.5 
44 12.0 12.0 
 
 
